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1.       Introduction  
 
 
 
1.1 Definitions and general concepts about 
pluripotent cells 
 
 
1.1.1  Stem cells and their differentiation potential 
during development 
 
A stem cell is a cell that has the ability of self-renewal for long 
periods (in case of adult stem cells for the whole life of an organism) 
as well as to give rise to the specialized cells that form the tissues and 
the organs of an organism, a process called differentiation. Based on 
their differentiation potential, stem cells are classified as totipotent, 
pluripotent, multipotent or unipotent (Marshak et al. 2001).  
 
A totipotent stem cell has the ability to generate all cell types and 
tissues and to form an embryo. Totipotent are the zygote and the cells 
that result from its first divisions (like cells of the 2-cell stage 
embryo). These cells develop into all embryonic or extra-embryonic 
tissues (like placenta and umbilical cord).  
 
A pluripotent stem cell can give rise to all types of cells of the three 
germ layers (ectoderm, mesoderm, endoderm) of an embryo but 
cannot form a viable organism. From these cells all cells arise that 
form an organism but not extra-embryonic tissues. Pluripotent cells 
are a number of cells developed in vitro, like embryonic stem cells 
(ESCs). Embryonic stem cells are cells isolated from the inner cell 
mass (ICM) of the embryo, that are further propagated ex vivo under 
specific culture conditions. ESCs closely resemble the cells of the 
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ICM from which they originate. However, whether ESCs and cells of 
the ICM are the same is a matter of dispute (Brook and Gardner 1997; 
Pelton et al. 1998).  
 
Finally, multipotent and unipotent stem cells are capable of 
differentiating along some or only one lineage. This applies to 
progenitor (precursor) cells or adult stem cells, that are responsible for 
derivation and steady-state self renewal of a tissue or an organ, and 
can give rise to cell types only of some tissues or organs (Ralston and 
Rossant 2005). 
 
An overview of early stages of development as well as differentiation 
potential of cells from the three germ layers is depicted in Figure 1 of 
Appendix 1.  
 
 
1.1.2  Defining pluripotency 
 
As mentioned above, pluripotency is defined from the potential of 
cells to differentiate into all three primary germ layers of the embryo, 
an ability observed in the cells forming the inner cell mass of the 
blastocyst. During the last three decades isolation and cultivation of 
pluripotent cells has been possible from a number of sources and 
under specific culture conditions. Laboratory-based criteria for testing 
the pluripotent state of these cells in mouse include three types of 
experiments: a. Formation of chimeras after injection of these cells 
into a blastocyst and transfer to the uterus of a pseudopregnant female 
mouse (and the ability of integrating into all tissues). b. formation of 
teratomas after injection of these cells into a genetically identical or 
immunodeficient adult mouse. c. In vitro differentiation into cell types 
of all three germ layers (Kirschstein and Skirboll 2001). 
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In addition, properties of a pluripotent cell include: 
 
• Ability of long-term self-renewal 
• Normal karyotype during long term culture 
• Ability of colonizing the germ line during the formation of 
chimeras and giving rise to eggs or sperm cells 
• Clonogenic, that is a single cell can give rise to a colony of 
genetically identical cells, or clones, which have the same 
properties as the original cell 
• Expression of the transcription factor Oct-4 
• Lack of the G1 checkpoint in the cell cycle 
(Kirschstein and Skirboll 2001; Lensch et al. 2006) 
 
In fact, all these are characteristics of ESCs and confirmation or 
rejection of pluripotency of a cell type is often based on its similarities 
or differences with ESCs. Thus, often the term pluripotent cells is 
synonymous with that of ESCs.  
 
 
1.1.3  Types of pluripotent cells in mouse 
 
Based on the source from which pluripotent cells originate, the 
following types of pluripotent cells have been derived in mouse: 
 
• Embryonic stem cells (ESCs): The ‘gold standard’ of pluripotent 
cells, isolated from the ICM of the early blastocyst (Evans and 
Kaufman 1981). 
 
• Embryonic germ cells (EGCs): Derived from primordial germ 
cells (PGCs), precursors of the germ cell line in the embryo 
(Hogan 2001; Rohwedel et al. 1996). 
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• Embryonic carcinoma cells (ECCs): Derived from testicular 
teratocarcinomas. They can be regarded as the malignant 
counterparts of ESCs (Andrews et al. 2001). 
 
• Multipotent adult germline stem cells (maGSCs): Derived 
recently from the adult mouse testis. They are extensively 
described later. 
 
• Induced pluripotent stem cells (iPS cells): Somatic cells 
reprogrammed to a pluripotent state by ectopic expression of 
defined factors (Meissner et al. 2007). 
 
Figure 1 and Appendix 1 (Fig. 2 of Appendix 1) depict the different 
pluripotent cell types, their origin and their main properties. 
 
 
oocyte
sperm
ECCs
ESCs
EGCs
maGSCs
Mesoderm Endoderm Ectoderm
In vitro culture
Injection into 
blastocyst
Ectoping 
grafting
In vitro 
culture
PGCs
In vitro culture
SSCs
Differentiation into
Zygote
Blastocyst
A.
Zo
vo
ili
s
(1)
(1)
(2)
(2) (3)
(3)
(4)
(4)  
 
Fig 1.   Properties of the different types of pluripotent cells. The diagram on the 
left represents the origin of these cells in vivo and their position in 
developmental time line. The arrows represent in vivo or in vitro processes in 
which one cell type can develop or be transformed into another.  
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1.2 Multipotent adult germline stem cells in mouse 
and their potential  
 
 
Until recently the only cells apart from ESCs that fulfilled, although 
partially, the criteria for pluripotency in mouse were EGCs and ECCs. 
However, ESCs and EGCs face immune reaction after transplantation 
and there are ethical issues regarding the usage of embryos, while use 
of ECCs is excluded due to malignant nature of these cells. Thus, 
identification of an alternative source for pluripotent cells is crucial 
for use in regenerative medicine.  
 
Several studies during the last five years have revealed that the 
germline lineage retains the potential to generate pluripotent cells (for 
a comprehensive review see de Rooij and Mizrak 2008). In 2004, 
ESC-like cells were found in germ stem cell cultures established from 
neonatal mouse testis and were designated as multipotent germline 
stem cells (mGSCs). These ESC-like cells are phenotypically similar 
to ESCs and EGCs, except in their genomic imprinting pattern. They 
differentiated into various types of somatic cells in vitro under 
conditions used to induce the differentiation of ESCs and produced 
teratomas after inoculation into mice. Furthermore, these ESC-like 
cells formed germline chimeras when injected into blastocysts 
(Shinohara et al. 2004). 
 
In 2006, the group of Prof. Engel in Goettingen isolated and cultured 
for the first time spermatogonial stem cells (SSCs) from the adult 
mouse testis which respond to culture conditions and acquired ESC-
like properties  (Guan et al. 2006). SSCs were isolated from adult 
mice transgenic for EGFP under Stra8 promoter (which is active in 
spermatogonia) and Rosa 26-LacZ. The authors proved that the 
pluripotency and plasticity of these cells, which were named 
multipotent adult germline stem cells (maGSCs), is similar to ESCs. 
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maGSCs are able to spontaneously differentiate into derivatives of the 
three embryonic germ layers in vitro, to generate teratomas in 
immunodeficient mice and to contribute to the development of various 
organs when injected into an early blastocyst.  
 
Isolation of SSCs and the derivation of maGSCs is not restricted to 
EGFP+ cells from the transgenic Stra8-EGFP/ROSA26-LacZ mouse 
(Stra8 mouse). ESC-like cell lines were also successfully derived from 
testes of four different strains of mice (FVB, C57BL/6, 129/Sv and the 
transgenic Stra8 mouse) by morphological criteria only. These results 
were confirmed by other groups (Izadyar et al. 2008; Seandel et al. 
2007).   
 
It is not yet clear whether SSCs are pluripotent themselves or 
generation of maGSCs in vitro may result from genetic 
reprogramming of SSCs in culture. Interestingly, another group 
showed recently that a single spermatogonial stem cell can 
dedifferentiate from a highly lineage-specified state to a pluripotent 
state (Kanatsu-Shinohara et al. 2008).  
 
The possibility to derive pluripotent stem cells from the adult testis 
has important implications for germ cell biology and opens the 
possibility of using these cells for biotechnology and medicine.  
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1.3  Critical pathways controlling pluripotency in 
mouse  
 
The most critical pathways regulating self-renewal in mouse ESCs are 
those mediated by leukaemia inhibitory factor (LIF) and Oct-4. LIF, a 
member of the LIF–oncostatinM–Il-6 superfamily of cytokines, is 
necessary for maintenance of feeder-free ESC lines. This activity is 
mediated through activation of STAT3 and the transcription factor c-
Myc, which is believed to be a key target of LIF-STAT3 signalling 
(Matsuda et al. 1999; Niwa et al. 1998)  
 
Equally important for maintaining the ESC state is the octamer motif 
binding transcription factor Oct-4. ESC lines express high levels of 
Oct-4 which are required to maintain the ESC state, and are 
downregulated upon differentiation (Buitrago and Roop 2007; Nichols 
et al. 1998; Pesce et al. 1999; Schoeler et al. 1989). Oct-4 itself 
cooperates with other transcription factors to positively and negatively 
regulate downstream gene expression. The most important are Sox-2 
and Nanog. These factors form the core of an extensive transcriptional 
network that control pluripotency in ESCs, by controlling each other 
as well as a big number of target genes (Rodda et al. 2005; Pan and 
Thomson 2007; Masui et al. 2007; Wang et al. 2007) (Fig. 3 of 
Appendix 1).  
 
In addition, a number of other pathways also occur in ESCs acting in 
cooperation or in parallel with LIF-STAT3 and Oct-4 pathways like 
BMP and Wnt pathways, while pluripotency regulators include also 
heterochronic genes, genes involved in telomeric regulation and 
polycomb repressors (Liu et al. 2007).  
 
Recently a new group of noncoding RNAs, called miRNAs, has been 
implicated to play a key role in regulation of pluripotency in mouse 
ESCs and embryonic development.   
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1.4   microRNAs in pluripotency and development 
 
 
1.4.1 miRNAs overview 
 
According to the current convention, a mature miRNA is defined as a 
ssRNA of ~22 nucleotides in length which is generated by the RNase-
III-type enzyme Dicer from an endogenous transcript that contains a 
local hairpin structure.  
 
Two processing steps lead to mature miRNA formation in animals 
(Fig. 2). Firstly, pri-miRNA (the primary transcript produced by RNA 
polymerase II) is processed into a ~70-nucleotide precursor (or 
multiple precursors in case of miRNA clusters) in the nucleus by an 
RNase-III enzyme called Drosha (pre-miRNA). After this initial 
cleavage and export from the nucleus into the cytoplasm by Exportin 
5, each hairpin precursor is cleaved by Dicer into a small dsRNA 
duplex (miRNA/miRNA*), which finally results into the mature ~22nt 
miRNA.  
 
~50% of miRNAs are proved or postulated to be transcribed from a 
single polycistronic pri-miRNA (miRNA clusters), indicating that 
these miRNAs are co-ordinately regulated during development (Bartel 
2004; Bartel and Chen 2004). 
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(1) 
(2) 
(3) 
A.Zovoilis 
 
 
Figure 2. The current model for miRNA biogenesis and function. Blue legends 
(pri-miRNA, pre-miRNA and mature miRNA) depict the different processing 
stages leading from the primary transcribed RNA molecule to mature miRNA, 
whose sequence is shown in red (2). The hairpin RNA structure that enables this 
processing is depicted in yellow (1). The lower part of the figure shows miRNA 
mediated translational silencing of target mRNA. Partial sequence 
complementarity between the miRNA and the 3`untranslated region (UTR) of 
the mRNA (3) brings about repression of protein synthesis. RISC, RNA induced 
silencing complex.  
 
 
1.4.2 miRNAs function 
 
With more than 200 members per species in higher eukaryotes, 
miRNAs are one of the largest gene families accounting for ~1% of 
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the genome (Kim 2005). The predominant regulatory effect of 
miRNAs is to repress their target mRNAs. Mechanisms for this 
include translational repression and mRNA cleavage. The first seems 
to be the dominant regulatory mode in animals, while the second 
characterizes plants. It has been shown, that in animals the single-
stranded mature miRNA associates with a complex that is similar, if 
not identical, to the RNA Induced Silencing Complex (RISC) which is 
known to mediate siRNA silencing. The miRNA/RISC complex 
represses protein translation by binding to sequences in the 3' 
untranslated region of specific mRNAs (Ambros 2004).  
 
Recent studies have shown that miRNAs have key roles in diverse 
regulatory pathways, including control of developmental timing, 
hematopoietic cell differentiation, apoptosis, cell proliferation, 
carcinogenesis and organ development. Regulation of gene expression 
by miRNAs is realized by formation of complex regulatory networks, 
in which each miRNA can target many different mRNAs, and 
conversely, several different miRNAs can cooperatively control a 
single mRNA target (Esquela-Kerscher and Slack 2006; He L and 
Hannon 2004; Kim 2005).  
 
It was shown that the expression of certain genes is more dependent 
on the level of regulatory miRNAs than on the level of mRNAs that 
encode the proteins (Johnson et al. 2005). Taking into account this 
fact as well as that over one third of all human genes are predicted to 
be targeted by miRNAs, it becomes obvious that discovery of 
miRNAs adds a new dimension to our understanding of complex gene 
regulatory networks during development (Chen C et al. 2007). 
Identification of the first mouse ESC specific miRNAs five years ago 
implicated that the role of miRNAs in the regulation of gene 
expression may extend also to early embryonic development and 
pluripotency. 
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1.4.3 Embryonic stem cell specific miRNAs (ESC-
specific miRNAs) 
 
A set of miRNAs has been described to be ESC-specific in mouse, 
with their expression being repressed during ESC differentiation and 
undetectable in adult mouse organs. This set of miRNAs consists of 
miR-290, miR-291a-3p, miR-292-3p, miR-293, miR-294, miR-295 
(miR-290 family; Houbaviy et al. 2003) and miR-302a, miR-302b, 
miR-302c, miR-302d (miR-302 family; Strauss et al. 2006). 
 
In a previous work, miRNAs of the miR-290 family were shown to 
become repressed in embryoid bodies (EBs) prepared by culturing ES 
cells for 14 days in either the presence or absence of RA (retinoic 
acid). It was suggested that their expression is specific for pluripotent 
ES cells and is either silenced or downregulated upon differentiation 
(Houbaviy et al. 2003; Houbaviy et al. 2005). Another group 
confirmed the expression of these miRNAs as well as of those of miR-
302 family only in ESCs and EBs, and not in somatic tissues.  In 
addition, they reported a negative correlation in EBs between miRNAs 
of miR-302 family and differentiation time (Strauss et al. 2006; Chen 
C et al. 2007).  
 
These miRNAs are expressed in clusters (members of each miR-
family are transcribed as parts of the same pri-miRNA) and they have 
close homologues in human ESCs with the same expression profile 
during differentiation (Suh et al. 2004). However, their role in 
pluripotency is still not well defined. 
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1.5   Aims and experiments outline 
 
 
The past few years have seen remarkable progress in our 
understanding and identification of critical conserved pathways 
regulating self-renewal and pluripotency. However, much of our 
knowledge about these pathways has come from mouse ESC lines but 
underlying mechanisms controlling pluripotency in other types of 
pluripotent cells like maGSCs remain to be elucidated. 
 
The objective of the current study was to test similarities and 
differences  between pluripotent cells derived from adult mouse testes 
(maGSCs) and embryonic stem cells (ESCs) with respect to 
microRNAs (miRNAs).   
 
¾ The first question to be answered was whether ESCs and 
maGSCs are distinct or equivalent cell types from the viewpoint 
of global miRNA expression patterns. This question was 
addressed by the whole miRNA array expression profiling of 
maGSCs and ESCs and the validation of the results in maGSCs 
and ESCs from different mouse strains. 
 
¾ The second question was whether miRNAs previously classified 
as ESC specific are also expressed in maGSCs and ECCs and 
thus characterize generally pluripotency. To answer this question 
ESC and maGSC lines from different mouse strains as well as 
ECCs of the F9 teratocarcinoma cell line were studied. 
 
¾ The third question was whether expression of these miRNAs in 
maGSCs remains like ESCs stable during time and it is restricted 
only to undifferentiated maGSCs. To answer this question cells 
were tested after culture for 10 passages (35 days) under 
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standard ESC culture conditions and after pluripotency was lost 
due to differentiation. 
 
¾ The last question was which is the expression profile of these 
miRNAs during first stages of in vitro differentiation of 
pluripotent cells and whether there are similarities and 
differences between ESCs and maGSCs concerning this profile. 
To answer this, the time-dependent influence of different 
differentiation factors on this profile was evaluated.  
 
¾ To test whether the observed similarities and differences in 
miRNA expression are associated with the differentiation state 
of the cells, results were correlated with time-course and extent 
of pluripotency and differentiation markers expression.  
 
¾ Finally, results were associated with the pattern of expressed de 
novo DNA methyltransferases, which have been recently shown 
to be regulated by these miRNAs (Sinkkonen et al. 2008). 
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2.    Materials and Methods 
 
 
 
2.1    Materials 
 
 
2.1.1   Laboratory materials 
 
2.1.1.1   Molecular biology  
 
14 ml-centrifuge tubes   Corning, New York, USA 
Coverslips (24 x 60 mm)    Menzel-Gläser, Braunschweig 
Disposable filter Minisart NMI   Sartorius, Göttingen 
Falcon tubes     Schleicher and Schüll, Dassel 
Films       Kodak 
Filter tips       Biozym, Hessisch Oldendorf 
Glasware       Schott, Mainz 
Hybond C      Amersham, Braunschweig 
Microcentrifuge tubes    Eppendorf, Hamburg 
Microliterpipettes   Pipetman Gilson Abimed, 
Langenfeld 
PCR-tubes  Molecular BioProducts, San 
Diego, USA 
Petri plates      Greiner, Nürtingen 
Reaction tubes      Eppendorf, Hamburg 
Reaction tubes     (RNase-free) Brand, Wertheim 
Real-time pcr plates    Applied Biosystems, Darmstadt 
Tips without filter     Eppendorf, Hamburg 
Whatman blotting paper    Schleicher and Schüll, Dassel 
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2.1.1.2   Cell culture  
 
Cell culture flasks and plates Greiner, Nürtingen or Nunc, 
Wiesbaden 
Culture slides BD     Falcon, Heidelberg 
Cell culture pipettes    Sarstedt, Nümbrecht 
Cryocups  Greiner, Nürtingen or Sarstedt, 
Nümbrecht 
Filtering unit      Nalgene, Rochester, USA 
Pasteur pipettes      Brand, Wertheim 
6 or 10 cm Plates     Nunc, Wiesbaden 
Steril Filters      Sartorius, Göttingen 
13 ml-centrifuge plastic tubes  Sarstedt, Nümbrecht 
14 ml- centrifuge plastic tubes  Corning, New York, USA or 
Greiner, Nürtingen 
 
 
2.1.2   Laboratory equipment 
 
Accu-Jet       Brand, Wertheim 
Autoclave      Webeco, Bad Schwartau 
Beckman J2-21 Ultracentrifuge   Beckman, München 
Beckman JS-7.5 Centrifugerotor  Beckman, München 
Biophotometer      Eppendorf, Hamburg 
Branson sonifier 250  Heineman, Schwaebisch 
Gmuend 
Centrifuge Biofuge 13    Heraeus, Hanau 
Centrifuge Heraeus Megafuge 1.0  Heraeus, Hanau   
DNA Sequencer Modell Megabace 
1000       Amersham, Freiburg 
Eppendorf Centrifuge 5415 D   Eppendorf, Hamburg 
Eppendorf Centrifuge 5417 R   Eppendorf, Hamburg 
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Fluorescence microscope BX60   Olympus, Planegg 
Freezer VIPseries -86°C   Sanyo, Tokyo, Japan 
GeneAmp PCR System 9600  Perkin Elmer, Berlin 
HT 7900 Analyzer    Applied Biosystems 
Incubator IR Autoflow Incusafe   Sanyo, Tokyo, Japan 
Inverted microscope IX81    Olympus, Planegg 
Light microscope     Zeiss, Göttingen 
Microplate Reader 450   Bio-Rad, Muenchen 
Microwave  oven    Phillips, Hamburg 
Molecular Imager FX    Bio-Rad laboratories, München 
MWG Primus 96plus Thermocycler  MWG Biotech, Ebersberg 
Neubauer cell chamber   Schütt Labortechnik, Göttingen 
Pipettes       Eppendorf, Hamburg 
Power supply      Gibco BRL, Karlsruhe 
PTC-100 Peltier Thermal Cycler  Bio-Rad, München 
Spectrophotometer Ultraspec 3000  Amersham, Freiburg 
SpeedVac concentrator SVC 100H  Schütt, Göttingen 
Sterilbank HERAsafe    Heraeus, Hanau 
Thermomixer 5436     Eppendorf, Hamburg 
TurboblotterTM     Schleicher & Schüll, Dassel 
Ultra low remperature  
freezer -152°C     Sanyo, Tokyo, Japan 
UV-Transilluminator     Herolab, Wiesloch 
X-Ray Automatic Processor Curix 60  Agfa, München 
 
 
2.1.3   Chemicals, biochemical and biological materials 
 
1 kb DNA ladder     Invitrogen, Karlsruhe 
Agar       Difco, Detroit, USA 
Agarose       Invitrogen, Karlsruhe 
Ampicillin      Sigma, Deisenhofen 
Ampuwa       Fresenius, Bad Homburg 
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β-Mercaptoethanol     Gibco BRL, Eggenstein  
Bisacrylamide      Serva, Heidelberg 
Boric acid      Sigma, Deisenhofen 
BSA       Biomol, Hamburg 
Chloroform      Baker, Deventer, NL 
Coomassie Blue G-250    Sigma, Deisenhofen 
DAPI   Vector Laboratories, 
Burlingame, USA  
Diethyl pyrocarbonate (DEPC)   Sigma, Deisenhofen 
Dimethylformamid    Sigma, Deisenhofen 
Dimethylsulfoxid (DMSO)   Sigma, Deisenhofen  
Dithiotreitol (DTT)     Applichem, Darmstadt  
DMEM      PAN, Aidenbach  
dNTPs       Invitrogen, Karlsruhe 
Dye Terminator Mix     Applied Biosystems 
EDTA       Biomedicals, Eschwege 
Ethanol       Baker, Deventer, NL 
Ethidium bromide     Sigma, Deisenhofen  
FCS        PAN, Aidenbach  
Ficoll      Applichem, Darmstadt 
Gelatin       Sigma, Deisenhofen  
Glycerol       Invitrogen, Karlsruhe 
Glycine       Biomol, Hamburg 
HCl        Merck, Darmstadt 
HEPES       Merck, Darmstadt 
IPTG       Biomol, Hamburg 
Isopropanol      Merck, Darmstadt 
KCl        Merck, Darmstadt 
L-Glutamine      Gibco BRL, Eggenstein  
LIF        Chemicon, Temecula, USA  
Methanol       Merck, Darmstadt 
Milk powder      Roth, Karlsruhe 
Mineral oil      Sigma, Deisenhofen 
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Mitomycin C      Sigma, Deisenhofen  
NaCl       Merck, Darmstadt 
NaOH       Merck, Darmstadt 
Non-essential amino acids   Gibco BRL, Eggenstein  
NuPAGE MOPS SDS Running Buffer Invitrogen, Karlsruhe 
NuPAGE SDS Sample Buffer   Invitrogen, Karlsruhe 
Orange G       Sigma, Deisenhofen 
Paraformaldehyde     Merck, Darmstadt 
PBS         PAN, Aidenbach  
Penicillin/Streptomycin    PAN-Systems, Nürnberg 
Peptone       Roth, Karlsruhe 
Potassium acetate    Merck, Darmstadt 
Bio-Rad Protein Assay   Bio-Rad, Muenchen 
Restriction enzymes    Invitrogen, Karlsruhe 
Retinoic acid      Sigma, Deisenhofen  
Reverse transcriptase     Invitrogen, Karlsruhe  
RNase away      Biomol, Hamburg 
S.O.C medium        Invitrogen, Karlsruhe 
SDS        Roth, Karlsruhe  
SeeBlue Plus2 Pre-Stained Standart  Invitrogen, Karlsruhe 
Tris / HCl       Roth, Karlsruhe  
Tris base       Sigma, Deisenhofen 
TritonX-100      Roth, Karlsruhe  
TrypLE Express (Trypsin)    Gibco BRL, Eggenstein  
Trypsin / EDTA     PAN, Aidenbach  
Tween 20       Roth, Karlsruhe  
Yeast extract     Roth, Karlsruhe 
X-Gal       Biomol, Hamburg 
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2.1.4   Solutions and buffers 
 
2.1.4.1   Agarose gel electrophoresis 
 
5 x TBE buffer      445 mM Tris base 
445 mM Boric acid 
10 mM EDTA (pH 8) 
 
DNA loading buffer    15% Ficoll 400   
       1 mM EDTA  
       0.01% Orange G 
       10% Glycerin 
 
 
2.1.4.2    Frequently used buffers and solutions 
 
Elution buffer      1.5 M NaCl 
20 mM Tris/HCl (pH 7.5) 
1 mM EDTA 
 
TE buffer 10 mM     Tris/HCl (pH 8.0) 
1 mM EDTA 
 
Transfer buffer (1x)     25 mM Tris pH 8.3 
150 mM Glycin 
10 % Methanol 
 
Blocking buffer  I (B1)   150 mM NaCl 
10 mM Tris/HCl (pH 7.5) 
0,1% Tween20   
 
Blocking buffer  II (B2)   0,2% BSA  
0,1% Tween20 in PBS  
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dNTP-solution (25 mM)    100 mM dATP  
100 mM dCTP  
100 mM dGTP  
100 mM dTTP  
 
Fixation buffer      4% Paraformaldehyde in PBS  
 
IPTG       100 mM in H2O 
 
Protein lysis buffer    10 mM Tris HCl (pH 8,0)  
        1 mM EDTA 
       2.5% SDS 
       1 mM PMSF 
       Proteinase inhibitors 
 
P1-buffer       50 mM Tris/HCl (pH 8,0)  
10 mM EDTA  
100 µg / ml RNaseA  
 
P2-buffer       200 mM NaOH  
1% SDS 
 
P3-buffer   3,2 M Potassium acetate 
(pH5,0)  
 
X-Gal-solution   2% X-Gal in 
Dimethylformamide 
 
DEPC-water   0.1% (v/v)  
Diethylpyrocarbonate 
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Gelatin 0.1%  0.1% diluted in Ampuwa  
water and autoclaved 
 
 
2.1.5 Media and cells 
    
2.1.5.1 Eukaryotic cell culture media and cells 
 
Cell lines: 
 
Cell line Reference/Source 
F9 ATCC, Manassas 
NIH/3T3 Cell Bank of the Institute of Human Genetics in 
Goettingen 
ESC R1 Wurst and Joyner 1993 
(kindly provided by Prof. I. Adham in the Institute) 
ESC Stra8 Kindly provided by Mrs. J. Nolte in the Institute 
maGSC 
129SV 
Guan et al. 2006 
maGSC FVB Guan et al. 2006 
maGSC Stra8 Guan et al. 2006 
maGSC 
C57BL 
Guan et al. 2006 
 
ESC medium      DMEM 
0,1 mM non-essential amino-
acids 
1 mM Sodium pyruvate 
1 μM β-Mercaptoethanol 
2 mM L-Glutamine 
1 mM Penicillin / Streptomycin 
20% FCS 
(1, 000 U / ml LIF) 
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FB medium      DMEM 
2 mM L-Glutamine 
1 mM Penicillin / Streptomycin 
10% FCS 
 
FB freezing medium    30% FB-Medium 
20% DMSO 
50% FKS 
 
ESC freezing medium    30% ESC-Medium 
20% DMSO 
50% FKS 
 
 
2.1.5.2 Bacteria culture media and cells 
 
Bacteria: 
 
Escherichia coli DH5α   
  
Invitrogen, Karlsruhe 
 
 
LB-medium (pH 7,5)     Peptone 5 g 
Yeast extract 2,5 g 
NaCl 5 g 
500 ml H2O 
 
S.O.C.-medium     Invitrogen, Karlsruhe 
 
 
For selection      Ampicillin (0,1 mg / ml) 
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For  Oja-Plates      100 μM IPTG 
0,4% X-Gal 
 
 
2.1.6   Vectors  
 
pGEM-T easy, Promega, Madison, USA 
 
 
2.1.7   Enzymes (with supplied buffers) 
  
Restriction enzymes       Invitrogen, Karlsruhe  
Platinum Taq DNA polymerase   Invitrogen, Karlsruhe 
 
 
2.1.8   Antibodies 
 
α-Tubulin       Sigma-Aldrich, T5168 
 
Anti-rabbit and anti-mouse  
IgG-Peroxidase antibodies     Sigma-Aldrich  
 
Oct-4 Abcam, Cambridge, 
ab19857 
 
Sox-2  Abcam, Cambridge,        
ab 15830 
 
SSEA-1 ES Cell Characterization 
Kit, Chemicon 
 
Anti-rabbit IgG Cy3-conjugated antibody  Sigma-Aldrich 
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2.1.9   Oligonucleotides 
 
Primer name Sequence
mVimentin-F 5-TGCAGTCATTCAGACAGGATGT-3
mVimentin-R 5-ATCTCTTCATCGTGCAGTTTCTTC-3
mHNF4-F 5-CCACATGTACTCCTGCAGGTTTAG-3
mHNF4-R 5-CGCTCATTTTGGACAGCTTC-3
mNestin-F 5-CTGCAGGCCACTGAAAAGTT-3
mNestin-R 5-ATTAGGCAAGGGGGAAGAGA-3
mNkx2.5-F 5-CCCAAGTGCTCTCCTGCTTTCC-3
mNkx2.5-R 5-GTCCAGCTCCACTGCCTTCTG-3
mBrachyury-F 5-CAATGGAGGGGGACAGATCAT-3
mBrachyury-R 5-AAGGGCTGTAATCTCCTCATTCTG-3
mDNMT3A2-F 5-AGGGGCTGCACCTGGCCTT-3
mDNMT3A2-R 5-TCCCCCACACCAGCTCTCC-3
mDNMT3B1/B6-F 5-TGGGATCGAGGGCCTCAAAC-3
mDNMT3B1/B6-R 5-TTCCACAGGACAAACAGCGG-3
mSdha-F 5-GCTTGCGAGCTGCATTTGG-3
mSdha-R 5-CATCTCCAGTTGTCCTCTTCCA-3
 
 
2.1.10   Kits 
 
Chemiluminescence kit  Santa Cruz Biotech., 
Santa Cruz, USA  
 
Dyenamic ET-Terminator Mix    Amersham, Freiburg 
 
ES cell characterization kit    Chemicon,Temecula,USA 
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miRCURY™ LNA microRNA  
Array microarray kit and power  
labeling kit        Exiqon, Vedbaek 
 
miRNeasy mini Kit      Qiagen, Hilden 
 
miScript Primer Assays     Qiagen, Hilden 
 
miScript Reverse Transcription Kit   Qiagen, Hilden 
 
miScript SYBR Green PCR Kit    Qiagen, Hilden 
  
Montage PCR      Millipore, Karlsruhe 
 
NuPAGE Pre-Cast Gel System   Invitrogen, Karlsruhe 
 
pGEM®T-easy Vector System I    Promega, Madison, USA 
  
QIAGEN Plasmid Mini Kit    Qiagen, Hilden 
 
Qiaquick Gel Extraction Kit    Qiagen, Hilden 
 
QuantiTect SYBR-Green PCR  
Master mix      Qiagen, Hilden  
 
 
2.2  Animal cell culture methods 
 
2.2.1 General animal cell culture procedures and 
conditions 
 
During working in the animal cell culture lab all rules regarding 
aseptic technique and "Good Cell Culture Practice" were followed, to 
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ensure all cell culture procedures are performed to a standard that will 
prevent contamination from bacteria, fungi and mycoplasma and 
cross-contamination with other cell lines. All cells were cultured in 
the appropriate culture flasks or plates in an incubator at 37°C in a 
humidified atmosphere of 5% CO2. Cells were grown to 80% 
confluence. 
 
 
2.2.2 Thawing of frozen cell lines, subculture and 
cryopreservation 
 
All cell lines that were used were obtained frozen from the institute`s 
culture collection. For revitalization, frozen cells were quickly thawed 
at 37°C water bath, gently transferred to disposable Falcon tubes 
containing 7 ml growth medium and spun down as described below. 
Supernatant was discarded by aspiration and cells were plated out 
after being resuspended in a suitable amount of prewarmed growth 
medium. 
 
Before confluence was reached, cells were subcultured. Cells were 
washed once with sterile PBS and incubated in minimal amount of 
trypsin solution (TrypLE™ Express) at 37°C until they had detached 
from the dish (5-10 min). The process was controlled under an 
inverted microscope. Trypsin activity was inhibited by addition of 
growth medium in which the cells were subsequently resuspended. 
100-200μl were removed and cell counting was performed, when 
necessary, using an improved Neubauer chamber. Then the cells were 
plated out or harvested for cryopreservation.  
 
For subculture resuspended cells were spun down (1,000xg for 5 min 
at RT). The supernatant was aspirated and the cells were resuspended 
in the suitable amount of prewarmed medium. Then the required 
number of cells was transferred to new labeled flasks containing pre-
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warmed medium (usually to a dil 1:3-1:4 of the initial cell number). 
For cryopreservation, after trypsinization, resuspended cells were spun 
down (1,000xg for 5 min). The supernatant was aspirated and the cells 
were resuspended in ice cold freezing medium. Cells were kept for 7 
days at -80°C, and then stored in liquid nitrogen. 
 
 
2.2.3   Cell quantification 
 
Under sterile conditions 100-200uL of cell suspension were removed 
and an equal volume of trypan blue was added. Both sides of the 
chamber were filled (10μl each) with cell suspension and viewed 
under a light microscope using x20 magnification. The number of 
viable cells (seen as bright cells) and non-viable cells (stained blue) – 
was counted. The concentration of viable and non-viable cells and the 
percentage of viable cells was calculated using the equations provided 
by the haemocytometer manufacturer.  
 
 
2.2.4  Preparation, maintenance and cryopreservation 
of MEFs and feeder layers 
 
Preparation of MEFs was done as follows: Pregnant mice at day 13.5-
15.5 p.c. where sacrificed. Using sterile forceps and scissors the 
abdominal cavity was opened and both uterine horns were dissected 
and placed in a Petri dish. After excess fat and mesentery were 
trimmed away, horns were opened under microscope and the 
conceptuses were released and transferred into a fresh dish containing 
PBS. Using forceps the embryonic membranes were opened, head was 
pinched off and internal organs were removed. The remaining was 
transferred into a conical glass tube containing small glass balls and 
0.125% trypsin/0.01%EDTA and incubated with magnetic agitation at 
37 °C for 20-40 min. Then FB medium was added to stop 
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trypsinization and cells were centrifuged for 10 min with 1,000 rpm. 
Pellet was resuspended in FB medium and cells were subsequently 
plated. 
 
When these flasks of primary MEFs were confluent, cells were 
passaged one more time before freezing and stored under liquid 
nitrogen in FB freezing medium. When needed cells were thawed and 
expanded for four more passages in gelatin coated flasks before 
inactivation. Inactivation was performed with 50 µl of 1mg/ml 
mitomycin C stock solution in 5 ml FB medium for 2-3 hrs. Then cells 
were cleaned with PBS and passaged into new gelatin coated flasks 
for direct use as feeder layers (FLs) after one day. 
 
 
2.2.5   Culture of ESCs and maGSCs 
 
After thawing of the frozen cells in ESC medium on feeder layers, 
cells were expanded for 1-2 passages before beginning of the 
experiments. Flasks were seeded as follows: T25 flask, 1-1.5 x 
106cells, 6 well plates, 4-5 x 104 cells. For preservation in an 
undifferentiated state cells were cultured on feeder layer (FL) in ESC 
medium in the presence of 1,000 U/ml recombinant mouse leukaemia 
inhibitory factor (LIF). Undifferentiated phenotype of the colonies 
was monitored daily in the microscope.  
 
For the differentiation studies, the following monolayer culture 
conditions were used:  
 
A. ESC medium with FL and LIF (FL+LIF), this is the standard ESC 
culture condition for maintenance of undifferentiated cells (untreated 
cells) ;  
B. ESC medium with FL, LIF and retinoic acid (RA; 10-6M) 
(FL+LIF+RA);  
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C. Cells were cultured in 0,1% gelatin coated culture flasks with ESC 
medium, without LIF (Gel);  
D. Cells cultured in 0,1% gelatin coated culture flasks with ESC 
medium, without LIF but with RA 10-6M (Gel+RA). 
 
 
2.2.6   Culture of F9 cells 
 
F9 cells were obtained from ATCC (Manassas, USA) and cultured as 
described previously (Nayernia et al., 2004) in FB medium in gelatin 
coated flasks. 
 
2.2.7   Culture of NIH/3T3 cells 
 
NIH/3T3 cells were cultured in FB medium in gelatin coated flasks. 
 
 
 
2.3    RNA isolation 
 
 
Plasticware or glassware was used after first eliminating possible 
RNase contamination. The isolated RNA was stored at -80ºC.   
 
 
2.3.1   Isolation of total RNA including miRNAs 
 
The common RNA purification protocols do not recover such small 
RNA molecules like miRNAs. For this reason, the miRNeasy Mini Kit 
was used for purification of total RNA, including miRNAs and other 
small RNA molecules. The method used by this kit combines 
phenol/guanidine-based lysis of samples and silicamembrane–based 
Materials and Methods                                                                                                             30  
       
___________________________________________________________________________ 
purification of total RNA. The lysis reagent which is included in the 
kit is a monophasic solution of phenol and guanidine thiocyanate, 
designed to facilitate lysis of tissues, to inhibit RNases, and also to 
remove most of the cellular DNA and proteins from the lysate by 
organic extraction. The maximal amount of starting material was 
determined based on manufacturer’s recommendations, so that the 
RNA binding capacity of the column is not exceeded. For this reason 
not more than 5 x 106 cells or 30 mg of tissue were used. Cells were 
trypsinized and counted, and after washing 1x with PBS cells were 
collected as pellet and homogenized by vortexing in 700 μl  lysis 
reagent (provided with the kit). The disruption and homogenization of 
tissues was carried out with mortar and pestle in the same amount of 
lysis reagent.  
 
After addition of 140 μl chloroform, the homogenate was separated 
into aqueous and organic phases by centrifugation at 12,000 x g for 15 
min at 4°C. RNA partitions to the upper, aqueous phase, while DNA 
partitions to the interphase and proteins to the lower, organic phase or 
the interphase. The aqueous phase was extracted, and ethanol (1.5 
volumes) was added to provide appropriate binding conditions for all 
RNA molecules from 18 nucleotides (nt) upwards. The sample was 
then applied to the RNeasy Mini spin column, where the total RNA 
binds to the membrane and phenol and other contaminants are 
efficiently washed away with the provided  RWT and RPE buffers 
according to manufacturer’s protocols. RNA was then eluted in 30 μl 
RNase-free water. To obtain a higher total RNA concentration, a 
second elution step was performed by using the first eluate. 
 
 
2.3.2   Determination of nucleic acid concentration 
 
The concentration of nucleic acids was determined 
spectrophotometrically by measuring absorption of the samples at 260 
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nm. The quality of nucleic acids i.e. contamination with salt and 
protein was checked by measurements at 260, 280, and 320nm. The 
concentration was calculated according to the formula: 
C = (E 260 – E 320)fc 
C = concentration of sample (µg/µl) 
E 260= ratio of extinction at 260 nm 
E 320= ratio of extinction at 320 nm 
f = dilution factor 
c = concentration (standard) / absorption (standard) 
for RNA : c = 0.04 µg/µl 
 
 
 
2.4   microRNA array experiments 
 
 
For microRNA Array experiments the miRCURY™ LNA microRNA 
Array microarray kit (Exiqon) was used together with the  
miRCURY™ LNA microRNA Array power labeling kit (Exiqon). 
Hybridizations and scanning of the slides were carried out in the 
special equipped ozone free laboratory of the Microarray Facility of 
University of Goettingen. Experiment design, image acquisition and 
quantification was performed in cooperation with Dr. Salinas and Mr. 
Opitz of this lab.  
 
2.4.1   Labeling of RNA molecules  
 
1 µg of total RNA containing small RNAs (and miRNAs) was used 
per labeling reaction per slide hybridization according to 
manufacturer’s recommendations. Prior to labeling integrity of the 
RNA was assessed on an Agilent Bioanalyzer (RIN values in Figure 4 
of Appendix 2). The miRCURY™ LNA microRNA Array Power 
labeling kit was applied for labeling RNA molecules with a single 
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fluorophore per molecule following a 2-step protocol provided by the 
manufacturer. The first step includes a Calf Intestinal Alkaline 
Phosphatase for removal of 5’-phosphates from terminal of the 
microRNAs (CIP treatment). In the second step, a fluorescent label is 
attached enzymatically to the 3’-end of the miRNAs in the total RNA 
sample. This is followed by an enzyme inactivation step after which 
the sample is ready for hybridization. In all experiments a dual color 
hybridization with Hy3™ and Hy5™ labeled RNA was performed, in 
which each CIP treated RNA sample was labeled with either Hy3™ or 
Hy5™ (dyes are equivalent to Cy-3 and Cy-5 dyes). 
 
To assure optimal labeling and hybridization, spike-in control probes 
(Spike-in miRNA kit) supplied in the miRCURY™ LNA microRNA 
Array microarray kit were used. The miRCURY™ LNA microRNA 
Array Spike-in kit contains 10 different synthetic unlabeled miRNAs 
in different concentrations. The set was spiked into each  RNA sample 
prior to labeling so that the synthetic Spike-in miRNAs would 
hybridize to corresponding capture probes on the miRCURY™ LNA 
microRNA Array. Spike-in miRNAs are provided at concentrations 
compatible with endogenous miRNA expression levels aimed at 
spanning the whole intensity range of miRNAs in most tissue samples. 
The corresponding capture probes are printed once in every subgrid, 
thus 32 times each. 
 
The spike-in miRNAs were added in equal amounts to labeling 
reactions before the dual-color array hybridizations, so that the signals 
from the spike-in capture probes could be used as a control of the 
labeling reaction and hybridization and as a help in deciding scanner 
settings between channels. In addition they were used as a control of 
the data normalization procedure, to estimate the variance of 
replicated measurements within arrays and to assess technical 
variability between different parts of the array. 
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2.4.2  Hybridization and washing of the arrays 
 
Each Hy3 labeled sample was mixed with a Hy5 labeled sample, 
denatured and then hybridized on a microarray slide according to the 
following schema: 
 
 
Slide No 
         Cy3 Cy5  A      B          C       D 
we01   1  -1  1     0        0    -1 
we02   1  -1  0     0        1    -1 
we03   1  -1  0     1       -1     0 
we04   1  -1  1    -1        0     0 
we05   1  -1 -1     1        0     0 
we06   1  -1  0    -1        1     0 
we07   1  -1  0     0       -1     1 
we08   1  -1 -1     0        0     1 
 
 
RNA from: 
A: ESC Stra8 (only in Exp A) 
B: maGSC Stra8 (only in Exp A) 
C: maGSC 129SV  
D: ESC R1  
 
Design layout of the experiments, with arrows representing  
hybridizations, is also shown in the results section. 
 
The miRCURY™ LNA microRNA Array layout was as follows: 
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The array was located on a standard size slide as illustrated in the 
drawing below (25.4 mm by 76.2 mm or 1 in by 3 in):  
 
 
(Source: Exiqon website, www.exiqon.com) 
 
The array carries the following specifications: 
• Outer dimensions: 17 mm wide by 37 mm long 
• Coordinates of first spot on slide = 4 mm, 15mm 
• 8 sub-arrays in 4 replicates 
• Spot size: 90 μm 
• Distance between spots: 225 μm 
 
The slides contained capture probes for all miRNAs in human, rat and 
mouse as annotated in miRBase release 11.0 . In addition, a number of 
capture probes are available for detection of human miRNAs not 
included in miRBase (miRPlus™ probes).  
 
In addition, thirty control capture probes were included in the probe 
set as follows: 
 
1.  Ten spike-in control probes to assure optimal labeling and 
hybridization (mentioned above). 
2. Eight negative capture probes. 
3. Twelve capture probes are included that hybridize to small 
nuclear RNAs. 
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Hybridization was carried out manually using an Agilent hybridization 
SureHyb chamber kit and gasket slide kit in hybridization buffer 
supplied with the Kit at 56°C for 16 hrs in a hybridization oven with 
rotation. Washing was carried out the next day according to 
manufacturer`s recommendations and then slides were dried and 
scanned. For image acquisition, quantification, normalization of the 
results and statistical analysis the software packages provided by the 
Facility were used. This part of the experiment was carried out in 
cooperation with the bioinformatician of the Facility, Mr. L. Opitz. 
 
 
 
2.5   RNA and microRNA expression analysis 
(Reverse Transcription PCR) 
 
 
Reverse Transcription PCR (RT-PCR) is a technique, which generates 
cDNA fragments from RNA templates, and thereafter amplifies them 
by PCR. It is very useful to determine the expression of genes in 
specific tissues or in different development stages. In the first step of 
RT-PCR, called the "first strand reaction", complementary DNA is 
made from a messenger RNA template using dNTPs and an RNA-
dependent DNA polymerase (reverse transcriptase) through the 
process of reverse transcription. RT-PCR exploits a characteristic of 
mature mRNAs known as the 3' polyadenylated region, commonly 
called the poly(A) tail, as a common binding site for poly(T) DNA 
primers. 
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2.5.1  Conversion of miRNAs and other small RNAs 
into cDNA 
 
Unlike mRNAs, miRNAs are not polyadenylated in nature. During the 
reverse transcription step, miRNAs are polyadenylated by poly(A) 
polymerase. Reverse transcriptase converts RNA (including miRNA, 
other small noncoding RNA, and mRNA) to cDNA using oligo-dT 
and random primers. Polyadenylation and reverse transcription are 
performed in parallel in the same tube. The miScript Reverse 
Transcription Kit was used which includes miScript Reverse 
Transcriptase Mix and miScript RT Buffer. miScript Reverse 
Transcriptase Mix is an optimized blend of enzymes comprising a 
poly(A) polymerase and a reverse transcriptase. miScript RT Buffer 
has been developed specifically for use with miScript Reverse 
Transcriptase Mix. This buffer system enables maximum activity of 
both enzymes. miScript RT Buffer also contains Mg2+, dNTPs, oligo-
dT primers and random primers.  
 
One μg of total RNA containing miRNAs was mixed with 4 μl of 
miScript RT Buffer and 1 μl  miScript Reverse Transcriptase Mix, 10 
mM dNTPs in a total volume of 20 μl. Samples were further incubated 
at 37°C for 60 min for the first strand cDNA synthesis. Next, the 
reaction was inactivated by heating at 95°C for 15 min and stored at -
20ºC. 
 
 
2.5.2   PCR  
 
Polymerase chain reaction (PCR) is a method that allows logarithmic 
amplification of short DNA sequences within a longer double stranded 
DNA molecule. After several (often about 40) rounds of 
amplification, the PCR product is analyzed on an agarose gel and is 
abundant enough to be detected with an ethidium bromide stain. For 
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reasons whose explanation is beyond the scope of this work, this 
method of analysis is at best semi-quantitative and, in many cases, the 
amount of product is not related to the amount of input DNA making 
this type of PCR a qualitative tool for detecting the presence or 
absence of a particular DNA. In order to measure messenger RNA 
(mRNA), the method was extended using reverse transcriptase to 
convert mRNA into complementary DNA (cDNA) which was then 
amplified by PCR and again analyzed by agarose gel electrophoresis. 
In many cases this method has been used to measure the levels of a 
particular mRNA under different conditions, but the method is 
actually even less quantitative than PCR of DNA because of the extra 
reverse transcriptase step. However, in this work this type of PCR was 
used preliminary to establish the optimal conditions and identify the 
right positive controls used later in qPCR. 
 
Semi-quantitative (regular) RT-PCR 
 
The amplification reactions were performed in automatic 
thermocyclers. The PCR reaction contains in general the following 
substances: 1 ng-10ng template DNA, 1 μl forward primer (10 pmol/ 
μl), 1 μl reverse primer (10 pmol/ μl), 1 μl 10 mM dNTPs, 5 μl 10x 
PCR buffer, 1.5 μl 50 mM MgCl2 and 1 μl Taq DNA polymerase (5 
U/ μl). The reaction mix was made up to 50 μl dd H20 and placed in a 
200 μl reaction tube and placed in thermocycler. A standard PCR 
program is as follows: Initial denaturation 95°C for 5 min followed by 
30-35 cycles of: 95°C for 30 sec (denaturation), 55°C - 65°C for 40 
sec (annealing, temperature depends on primer’s Tm value), 72°C for 
(extension, time depends on the PCR product, as 1 min for 1 kb 
DNA). Then a final extension step followed at 72°C for 10 min and 
then a step at 4°C for infinite time till the PCR tubes were taken from 
the PCR machine. The simplest formula for calculating the Tm 
(melting temperature) of the primers is: Tm= 4°C x (number of G’s 
and C’s in the primer) + 2°C x (number of A’s and T’s in the primer). 
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2.5.3   Real-time RT-PCR (qPCR) for miRNAs 
 
In contrast to regular RT-PCR and analysis by agarose gels, Real-time 
RT-PCR or quantitative PCR (qPCR) allows accurate quantification of 
starting amounts of cDNA targets. In Real-time PCR using SYBR 
green binding to amplified cDNA, we are simply measuring the 
fluorescence increase as the dye binds to the increasing amount of 
DNA in the reaction tube. SYBR Green I binds to all double-stranded 
DNA molecules, emitting a fluorescent signal of a defined wavelength 
on binding. The excitation and emission maxima of SYBR Green I are 
at 494 nm and 521 nm, respectively, and are compatible for use with 
any Real-time cycler. Detection takes place in the extension step of 
Real-time PCR. Signal intensity increases with increasing cycle 
number due to the accumulation of PCR product.  
 
The cDNA converted from total RNA containing miRNAs served as 
the template for Real-time PCR analysis using the miScript Primer 
Assay in combination with the miScript SYBR Green PCR Kit. The 
oligo-dT primers used in the reverse transcription step have a 
universal tag sequence on the 5' end. In the Real-time PCR step 
miRNAs are amplified using the miScript Universal Primer, which 
primes from this universal tag sequence, together with the miRNA-
specific primer (the miScript Primer Assay). A single cDNA 
preparation is sufficient to interrogate multiple miRNAs by Real-time 
PCR using different miRNA-specific primers. 
 
In this study miScript Primer Assays (available from Qiagen) for the 
following miRNAs were used:  
290_5p, 291_3p, 292_3p, 293, 294, 295, 302a, 302b, 302c, 302d, 19b, 
20b. 
 
Real-time RT-PCRs were performed in the respective cycler. The 
PCR reaction contained: 1 μl cDNA , 5 μl 2x miScript SYBR Green 
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PCR Master Mix, 1 μl 10x miScript Universal Primer, 1 μl 10x 
miScript Primer Assay and RNase free water to a total volume of 10 
μl dd H20 and placed into the individual wells of a 384-well plate. The 
PCR program was as follows: 50°C for 2 min, initial activation step 
95°C for 15 min followed by 40 cycles at 94°C for 15 sec 
(denaturation), 55°C for 30 sec (annealing) and 70°C for 30 sec 
(extension). Then a final dissociation curve (melting curve) was made, 
and PCR plates were kept at 4°C till they were taken out from the 
PCR machine. 
 
However, nonspecific PCR products and primer-dimers will also 
contribute to the fluorescent signal. Therefore, high PCR specificity is 
required when using SYBR Green I. A way to check that the correct 
fragments were amplified is to do a melting curve. After Real-time 
PCR amplification, the machine was programmed to do a melting 
curve, in which the temperature is raised by a fraction of a degree and 
the change in fluorescence is measured. At the melting point, the two 
strands of DNA will separate and the fluorescence rapidly decreases. 
The software plots the rate of change of the relative fluorescence units 
(RFU) with time (T) (-d(RFU)/dT) on the Y-axis versus the 
temperature on the X-axis, and this will peak at the melting 
temperature (Tm). If the peaks are not similar, this might suggest 
contamination, mispriming, primer-dimer artifacts etc. A primer-
dimer artifact would give a peak with a lower melting temperature 
(because it is such a short DNA).  
 
PCR specificity was checked i) by the melting curves mentioned 
above, ii) by gel electrophoresis and iii) by sequencing of the PCR 
products after gel extraction and cloning into a pGEM®T-easy 
Vector, which is mentioned below (representative results are shown in 
Figures 1-3 of Appendix 2). Based on these preliminary results, it was 
decided not to include miR-302c in this study, since the high amount 
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of unspecific products observed for this miRNA could not guarantee 
reliability of the results. 
 
Analysis of data 
 
Gene expression levels are calculated by determining the ratio 
between the amount of a target gene and an endogenous reference 
gene that is in all samples. This ratio is then compared between 
different samples. Usually, housekeeping or maintenance genes are 
chosen as endogenous reference. The target and reference gene are 
amplified separately from the same sample.  
 
The normalized value is determined for each sample and can be used 
to compare differential expression of a gene in different tissues. In this 
work relative quantification was carried out as follows: 
 
- RNU6B, whose expression level does not change under the 
experimental conditions or between different tissues was chosen as 
endogenous reference. 
- A dilution series of a cDNA control sample (ESC R1) was prepared 
to construct standard curves for target and reference genes. 
- CT values for the standards and samples of interest were determined. 
-Standard curves for both target and reference were constructed by 
plotting CT values (Y-axis) against the log of template amount or 
dilution (X-axis). 
- Amount of target and reference in samples of interest were 
calculated using CT value and corresponding standard curve.  
- The normalized amount of target was calculated by dividing the 
amount of target by the amount of reference (because replicate 
reactions were performed, average values were used). 
- The normalized target amount of one sample was set to 1 (calibrator 
sample) and relative expression level of target gene in samples of 
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interest was compared by dividing the normalized target amounts by 
the value of the calibrator. 
 
 
2.5.4   Real-time RT-PCR (qPCR) for mRNAs 
 
qRT-PCR for mRNAs was performed as for miRNAs with the 
following modifications: 5 µl 2x QuantiTect SYBR Green PCR 
Master Mix , 1 μl 10x Forward Primer, 1 μl 10x Reverse Primer, 0.3µl 
MgCl2  and RNase free water to a total volume of 10 μl. The PCR 
program was as follows: 50°C for 2 min, initial activation step 95°C 
for 15 min followed by 40 cycles of 95°C for 15 sec (denaturation) 
x°C for 30 sec (x=annealing temperature depending on the Tm of the 
used primers) and 72°C for 30 sec (extension).  
 
Primer sequences are provided in the oligos section. Sdha was used as 
endogenous reference. For standard curves, samples of 
undifferentiated or differentiated ESCs and maGSCs were used. 
Selection of the appropriate sample for the standard curve was based 
on preliminary experiments testing detection of expression of each 
gene by RT PCR in the sample with the respective annealing 
temperature and for 35 cycles. As in miRNAs, specificity of the PCR 
products was confirmed with subsequent cloning and sequencing 
while reliability of Real-time PCR data was also assessed in 
connection with the respective dissociation curves. 
 
 
2.5.5   Gel electrophoresis 
 
Gel electrophoresis is the technique by which a mixture of charged 
macromolecules, especially nucleic acids and proteins are separated in 
an electrical field according to their mobility which is directly 
proportional to macromolecule’s charge to mass ratio. 
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PAGE electrophoresis 
 
PAGE electrophoresis was used at the beginning to separate the 
products of miRNAs qPCRs, since these were expected to be <50bp 
and this method provides a better separation in these sizes. However, 
it was found that due to the universal adaptor added by the kit, 
products were >70bp and thus in the following experiments regular 
agarose gel electrophoresis was applied.  
 
Agarose gel electrophoresis 
 
Agarose gels are used to electrophorese nucleic acid molecules from 
as small as 50 bases to more than 50 kilobases, depending on the 
concentration of the agarose and the precise nature of the applied 
electrical field (constant or pulse). Usually, 1 g of agarose was added 
in 100 ml 0.5x TBE buffer, boiled in the microwave to dissolve the 
agarose, then cooled down to about 60°C before adding 3 μl ethidium 
bromide (10 mg/ml). This 1% agarose gel was poured onto a 
horizontal gel chamber. For running of products of miRNA Real-time 
PCR for subsequent cloning, 3,5% agarose gels were used. 
 
 
 
2.6   Methods for subcloning and sequencing of RT-
PCR products  
 
 
2.6.1   Gel extraction 
 
QIAquick gel extraction method: This method is designed to extract 
and purify DNA from agarose gels. Up to 400 mg agarose can be 
processed per spin column. The principle of this method depends on 
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selective binding of DNA to uniquely designed silica gel membranes. 
Excised DNA fragments in agarose were isolated as described in 
QIAquick Spin Handbook supplied by the producer (Qiagen). In brief, 
to the excised DNA fragment from agarose gel, 3 volumes of QG 
buffer were added and then incubated at 50°C for 10 min. After the 
gel slice was dissolved completely, the solution was applied over a 
QIAquick column and centrifuged. The flow through was discarded 
and the column was washed with PE buffer. After drying the column, 
it was placed into a fresh microcentrifuge tube. To elute DNA, 50 μl 
of EB buffer was applied to the centre of the QIAquick membrane and 
centrifuged. 
 
 
2.6.2   Ligation 
 
Taq and other polymerases have a terminal transferase activity that 
results in the nontemplate addition of a single nucleotide to the 3' ends 
of PCR products. In the presence of all 4 dNTPs, dATP is 
preferentially added. This terminal transferase activity is the basis of 
the TA - cloning strategy. For cloning of these PCR products, the 
pGEM®T-easy Vector system that has 5‘dT overhangs was used. The 
following constituents were mixed:  
50 ng of pGEM-T Easy vector  
PCR product (1:3 vector to insert ratio)  
1 μl T4 DNA Ligase 10x buffer  
1 μl T4 DNA Ligase  
in a total volume of 10 μl. The content was mixed by pipetting and the 
reaction was incubated at RT for 3 hrs for inserts originating from 
mRNAs, and at 4 C overnight for inserts originating from miRNAs. 
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2.6.3   Transformation of competent bacteria 
 
Transformation of the bacteria was done by gently mixing one aliquot 
of competent bacteria (50 µl) with 10 µl of ligation reaction. After 
incubation for 30 min on ice, bacteria were heat shocked for 45 sec at 
42°C and cooled down for 5 min on ice. After adding 900 µl of S.O.C. 
medium, bacteria were incubated at 37°C with shaking for 1 hr to 
allow recovery of heat shocked bacteria. They were then plated out on 
LB-agar plates containing ampicillin (50µg/ml) and whenever 
required 1 mM IPTG and X-Gal 40 mg/ml were added for “Blue-
White” selection.  
 
 
2.6.4   Cloning 
 
A single Escherichia coli colony was inoculated in 5 ml of LB 
medium with ampicillin and incubated in a shaker for 16 hrs at 37°C 
with a speed of 160rpm. 
 
 
2.6.5 Small-scale isolation of plasmid DNA (Mini 
preparation) 
 
 
One ml of the above mentioned saturated culture was used for making 
glycerol stocks and rest of the culture was centrifuged at 5,000xg for 
15 min. Bacterial glycerol stocks were made suspending 500 μl 
bacteria in 300 μl 80% (v/v) sterile glycerol. The suspension was 
mixed well and stored at –80°C. The pellet was resuspended in 100 μl 
of solution P1. The bacterial cells were lysed with 200 μl of P2 
solution and then neutralized with 150μl of solution P3. The 
precipitated solution was incubated on ice for 15 min and centrifuged 
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at 13,000xg at 4°C. The supernatant was transferred into a new tube 
and centrifuged again for 10 min at 13,000xg. To the supernatant 1 ml 
of 100% ethanol was added to precipitate the DNA. It was then stored 
on ice for 15 min, centrifuged at full speed for 20 min, and  finally the 
pellet was washed with 70% ethanol and after air dried it was 
dissolved in 30 μl of TE buffer.   
 
 
2.6.6   Digestion 
 
Successful ligation and cloning was confirmed through digestion of 
the plasmid DNA with the restriction enzyme recommended from 
pGEM®T-easy manufacturer, the EcoRI. Restriction enzymes are 
class of bacterial enzymes that cut DNA at specific sites. Restriction 
enzyme digestion was performed by incubating the plasmid DNA with 
the appropriate amount of restriction enzyme in its respective buffer as 
recommended by the supplier, and at 37°C for 90 min.   
 
 
2.6.7   Cleaning of DNA sample 
 
For successful downstream applications, isolated plasmid DNA should 
be of high purity. To clean the plasmid DNA from undesired 
byproducts of previous isolation processes, the Montage PCR Kit was 
used, following the instructions recommended by the supplier.  
 
 
2.6.8   Sequencing 
 
The non-radioactive sequencing was achieved with Dye Terminator 
Cycle Sequencing-Kit. The principle of this is based on the Sanger 
method. The sequencing reaction was carried out in a total volume of 
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10 μl containing 1 μg plasmid DNA or 100-200 ng purified PCR 
products, 5 pmol primer and 3 μl reaction mix (contains dNTPs, 
dideoxy dye terminators and Taq DNA polymerase). Elongation and 
chain termination take place during the following program in a 
thermocycler: 5 min denaturing followed by 25 cycles: 95°C, 30 sec 
(denaturing); 55°C, 30 sec (annealing); 60°C, 2 min (elongation). 
After the sequencing reaction, the reaction products were analyzed 
with an automatic sequencing equipment, namely MEGA BACE 
1000. 
 
 
 
2.7    Protein expression analysis methods 
 
 
2.7.1   Protein extraction 
 
Proteins were extracted from ~30mg frozen mouse tissues (disrupted 
before by mortar and pestle) or from cells in pellets (105- 5 x 106 cells 
were previously trypsinized and pellets were washed with PBS) by 
homogenization in protein lysis buffer. Lysates were maintained on 
ice for 60 min and then sonicated on ice and centrifuged at 12,000xg 
for 10 min at 4°C. Supernatant was collected, quantified and stored at 
-80°C or used immediately for Western blotting. 
 
 
2.7.2   Determination of protein concentration 
 
To determine the protein concentration, Bio-Rad protein assay was 
employed, which is a dye-binding assay based on the differential 
colour change of a dye in response to various concentrations of 
protein. The assay is based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Blue G-250 shifts from 
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494 to 595 nm when the binding to protein occurs. The bovine serum 
albumin (BSA) stock solution of 1 mg/ml was diluted in order to 
obtain standard dilutions in range of 10 µg/ml to 100 µg/ml. The Bio-
Rad’s color reagent was diluted 1:5 with H2O and filtered through 
0.45 µm filters. In a 96-well microtiter plate, 20 µl of each standard 
dilution and the samples to be measured were pipetted with 280 µl of 
the colour reagent. The absorption of the colour reaction was 
measured at 595 nm in a microplate reader (Microplate Reader 450, 
Bio-Rad). 
 
 
2.7.3   SDS-PAGE for the separation of proteins 
 
The NuPAGE Pre-Cast Gel System (Invitrogen) is a polyacrylamide 
gel system for high performance gel electrophoresis and is based on 
SDS-PAGE gel chemistry. It consists of NuPAGE Bis-Tris Pre-Cast 
Gels and specially optimized buffers which have an operating pH of 
7.0. The NuPAGE System is based upon a Bis-Tris-HCl buffered (pH 
6.4) polyacrylamide gel, with a separating gel that operates at pH 7.0. 
While NuPAGE Bis-Tris Gels do not contain SDS, they are 
formulated for denaturing gel electrophoresis applications only.  
 
7,5 μl of NuPAGE LDS Sample Preparation Buffer 4x (pH 8.4) were 
mixed with 2 μl DTT 0,1M, 20 μg of whole protein extract and water 
to a total volume of 30 μl. The samples were denaturated by heating in 
70ºC for 10 min and cooled at ice for 5 min. Samples were then 
loaded in NuPAGE Bis-Tris Gels of acrylamide concentration of 10% 
and run in 1 x NuPAGE MOPS Buffer at 60 V for about 3,5 hrs at RT 
producing an expected separation range. To determine the molecular 
weight of the proteins on the gel, 10 µl of a pre-stained molecular 
weight standard (See Blue Plus2, Invitrogen) was also loaded.  
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2.7.4   Western blotting 
 
After the electrophoresis of proteins the gel and the Hybond-C Extra 
membrane, which was cut at the size of the gel, were first moistened 
in transfer buffer. 10 pieces of GB004 Whatman filter paper were also 
cut at the size of the gel. First, five papers soaked with transfer buffer 
were placed on blotting machine’s lower plate and then membrane 
was placed over them. Next the gel was placed avoiding any air 
bubbles. Another 5 Whatman papers soaked with transfer buffer were 
placed over to complete the sandwich model. The upper plate was 
placed over this sandwich and the transfer was carried out at 150mA 
for 15 min and 300mA for 60min. Membrane was then used for 
incubation with antibodies. To confirm transfer efficiency of proteins 
onto the membranes, the gel was incubated for 30 min in Coomassie 
blue solution at RT.  
 
The membrane was first incubated in blocking buffer I (B1) with 5% 
non-fat dry milk for 1 hr at RT in order to block unspecific binding 
sites, followed by incubation with 2% milk in B1 buffer for 5 min. 
Membrane was then incubated with a primary antibody at the 
recommended antibody dilution in buffer B1 with 2% non-fat dry milk 
for overnight at 4°C. Then, the membrane was washed 3 times in B1 
buffer with 2% dry milk for 60 min and then incubated with the HRP 
conjugated secondary antibody in B1 buffer with 2% non-fat dry milk 
for 1 hr at 4°C. After this step, the membrane was washed 3 times in 
B1 buffer with 2% dry milk, one time in PBS for 5 min at 4°C. 
Finally, protein bands were visualized using enhanced 
chemiluminescence as described by the manufacturer (Santa Cruz 
Biotech.). When the expected band size allowed it, membranes were 
reused for one more time and were incubated with another primary 
antibody after blocking. The following antibodies were used: α-
Tubulin (dil 1:5,000), Oct-4 (dil 1:500), Sox-2 (dil 1:1,000), and the 
respective anti-rabbit or anti-mouse IgG-Peroxidase antibodies. 
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2.7.5   Immunocytochemistry 
 
First, the culture media was removed from the cells in microscopical 
chambers and cells were rinsed with PBS. After that 1 ml 4% PFA 
(made fresh) per chamber was added and incubated for 10 min at RT 
for fixing the cells. Then, the cells were washed 3 times with PBS and 
permeabilized by adding 1 ml blocking buffer II / plate containing 
Triton X-100. The permeabilization was carried out for 10 min at RT. 
After washing, the cells were blocked in blocking buffer II and 
incubated with the respective diluted primary antibody for 1 hr to 
overnight at 4°C. Then cells were washed again and stained with the 
secondary antibody diluted in the same buffer applied for primary for 
1 hr at RT. For immunofluorescence staining of SSEA-1, the antibody 
contained in the ES Cell Characterization Kit (Chemicon) was used. 
An anti-rabbit IgG Cy3-conjugated antibody (Sigma-Aldrich) was 
used as secondary antibody. Slides were viewed in a BX60 
fluorescence microscope (Olympus). Before microscopical analysis 
the cells were rinsed 2 times with PBS and mounted with DAPI 
(Vector). 
 
 
 
2.8    Bioinformatics methods and software 
 
 
2.8.1  Statistical analysis of data 
 
For statistical analysis of data, the STATISTICA software was used. 
Data are expressed as the mean ± SD. A one-way analysis of variance 
(ANOVA) followed by Fischer LSD’s multiple comparison tests was 
used for statistical analysis with P less than 0.05 considered 
statistically significant. 
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2.8.2   miRNA target prediction 
 
For prediction of miRNA targeting sites in mRNAs` 3`UTRs the 
TARGETSCAN Software was used (www.targetscan.org).  
 
 
2.8.3   Sanger miRNA database (miRBase) 
 
All miRNA sequences were provided by or correlated with the 
sequences stored in the Sanger miRNA data base 
(http://microrna.sanger.ac.uk).  
 
 
2.8.4   Blast 
 
The obtained DNA sequences were analyzed with a BLAST program 
by using the sequence data base Genbank (www.ncbi.nlm.nih.gov) 
and EMBL (www.ebi.ac.uk). 
 
 
2.8.5   Western blotting density determination software 
 
Levels of Oct-4 and Sox-2 from Western blots of two independent 
experiments were quantified densitometrically with QuantityOne 
software (Bio-Rad) and normalized to α-Tubulin.  
 
 
2.8.6  SDS software 
 
Visualization and primary raw data processing of the qPCR results 
was performed by the SDS Software. 
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2.8.7  Microsoft Excel 
 
Processing of the qPCR raw data and visualization of the results was 
done using teh Microsoft Office Excel Software. 
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3.  Results 
 
 
 
3.1 microRNA array expression profiling of maGSCs 
compared with ESCs 
 
 
In order to address the question whether ESCs and maGSCs are 
distinct or equivalent cell types from the viewpoint of miRNA 
expression patterns, the global miRNA expression profiles of maGSCs 
and ESCs were examined by miRNA arrays. 
 
miRNA array analysis was carried out for two maGSC lines,  maGSC 
129SV and maGSC Stra8, and their respective ESC lines, ESC R1 and 
ESC Stra8. Every hybridization was performed in duplicates (two 
identical slides for each comparison/hybridization), and every miRNA 
was present four times on each slide. The experiment layout was 
designed as follows (each arrow depicts one hybridization, as 
described in Materials and Methods): 
 
   Experiment A: 
 
maGSCStra8
ESC R1maGSC129SV
ESC Stra8
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This layout allows the simultaneous comparison of each cell line with 
all others ensuring at the same time the statistical validity of the 
results (four technical replicates).  
 
In case of maGSC 129SV and ESC R1 the experiment was carried out 
one more time (Experiment B), with the same number of technical 
replicates, as follows: 
 
   Experiment B: 
 
ESC R1maGSC129SV
 
2x 
 
In this case maGSC 129SV and ESC R1 were cultured independently 
from cells of Experiment A to allow their use as a biological replicate. 
 
miRNA arrays tested included more than 1700 capture probes, 
covering all human, mouse and rat microRNAs annotated in miRBase 
11.0, as well as all viral microRNAs, related to these species. The 
coverage of this array to the latest miRBase version (miRBase 12.0) is 
98%, 97% and 100% for human, mouse and rat, respectively 
(http://microrna.sanger.ac.uk). In this study only mouse miRNAs  
were of interest. More information about the array contents and layout 
are mentioned in Materials and Methods section 2.4.2. The array 
results are presented in Tables 1, 2 and 3 and in Appendix 6.  
 
maGSC Stra8 cells were found to differ from all other cell lines tested 
concerning miRNA array expression profiling. In detail, five out of 
nine differentially expressed miRNAs between ESC Stra8 and maGSC 
Stra8 differ also in the comparisons of maGSC Stra8 with maGSC 
129SV and ESC R1. These miRNAs (marked with orange 
highlighting/Table 1) are the following: miR-762, miR-494, miR-720, 
miR-711 and miR-689. Four others (miR-184, miR-712*, miR-21 and 
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miR-301a) were found to differ only between maGSC Stra8 and the 
respective ESC line (Table 1). 
 
 
ESC Stra8 <
miR-762
miR-494
miR-720
miR-711
miR-689
miR-184
miR-712*
miR-21
miR-301a
ESC Stra8 >
m
aGSC
Stra8
 
 
Table 1. Differentially expressed miRNAs between ESC Stra8 and the 
respective maGSCs (maGSC Stra8).< and > depict lower or higher expression 
levels respectively of these miRNAs in ESC Stra8 compared with maGSC Stra8. 
x-fold changes and statistical values are presented in Appendix 6. 
 
 
In contrast, all the differences observed between ESC R1 and maGSC 
129SV were specific only for this comparison (Table 2/Exp A). When 
the experiment was repeated (Table 2/Exp B), most of these 
differences were eliminated. In detail, most of the miRNAs that were 
found to be expressed in higher levels in ESC R1 belong to miR-17-92 
cluster (miR-17, mir-19b and miR-20a) or its paralogue miR-106a-
363 cluster (miR-106a and miR-20b). In addition, differential 
expression was found for members of miR-467 cluster and miR-803, 
as well as for miR-22 and miR-689 that were upregulated in maGSCs. 
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ESC R1<
miR-22
miR-689
ESC R1>
miR-20a
miR-17
miR-19b
20b
miR-467b
miR-467a* /467d*
miR-106a
miR-803
m
aGSC
129 SV
ESC R1<
22
689
ESC R1>
20a
17
miR-19b
miR-20b
467b
467a* /467d*
106a
803
Experiment A Experiment B
 
 
Table 2. Differentially expressed miRNAs between ESC R1 and the respective 
maGSCs (maGSC 129SV) in either experiment A or B. miRNAs differentially 
expressed in both experiments are marked with red.  < and > depict lower or 
higher expression levels respectively of these miRNAs in ESC R1 compared 
with maGSC 129SV. x-fold changes and statistical values are presented in 
Appendix 6. 
 
 
Finally,  most differences between the two maGSC lines belong either 
to these that are common between maGSC Stra8 and other cell lines 
mentioned above (marked with orange highlighting/Table 3), or could 
be genetic background related, since they are observed also between 
ESC Stra8 and ESC R1 (marked with green highlighting/Table 3). 
miRNAs that differed between the different maGSC lines but do not 
belong to the above mentioned groups (orange/green) consist of miR-
335_5p, miR-22, miR-294 and miR-142_3p. 
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maGSCStra8 <
miR-335_5p
miR-124
miR-182
miR-96
miR-183
miR-292_3p
miR-295
miR-22
miR-294
maGSCStra8 >
miR-762
miR-494
miR-720
miR-711
miR-689
miR-142_3p
miR-706
miR-142_5p
m
aGSC
129 SV
 
 
Table 3. Differentially expressed miRNAs between maGSC Stra8 and maGSC 
129SV. < and > depict lower or higher expression levels respectively of these 
miRNAs in maGSC Stra8 compared with maGSC 129SV. x-fold changes and 
statistical values are presented in Appendix 6. 
 
 
 
Detailed array results including P values and x-fold changes in 
miRNA expression are available in Appendix 6. 
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3.2 Validation of the array results in maGSCs from 
129/Sv and other mouse strains 
 
 
Since aim of this study was to shape the similarities and differences 
between ESCs and maGSCs, validation of the array results 
concentrated only in the miRNAs that differed between ESCs and 
maGSCs. In addition, since all other maGSC strains were derived 
similarly to maGSC 129SV, miRNAs differentially expressed in 
maGSC Stra8 were excluded from the validation procedure since 
derivation method of these cells (genetic selection for Stra8) seems to 
affect their gene expression signature. 
 
Most of miRNAs that differed between maGSC 129SV and ESC R1 
in Experiment A belonged to miR-17-92 cluster or its paralogue miR-
106a-363. Differences in two miRNAs from these families (miR-20b 
and miR-19b) persisted when the experiment was repeated (Exp B) 
(red highlighting/Table 2).  
 
qPCR was performed only for miR-20b and miR-19b that were found 
to differ in both experiments between ESC R1 and maGSC 129SV 
and confirmed the array results (Fig. 3).  
 
In addition maGSCs from mouse strains C57Bl and FVB were 
compared with their respective ESCs to find whether the differences 
in these two miRNAs are strain related or not. Figure 3 shows that 
differences observed in these miRNAs are restricted to 129/Sv 
background. In other strains, miRNA levels between maGSCs and 
ESCs were similar for these two miRNAs. 
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Figure 3. Expression levels of miR-19b and miR-20b detected by Real-time 
PCR in ESCs and maGSCs from different mouse strains. Expression levels are 
normalized to the expression of the endogenous control (RNU6B). ESC R1  was 
used as calibrator (cal). 
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3.3 Expression of miR-290 and miR-302 miRNA 
clusters in maGSCs and ECCs 
 
 
Expression of ESC-specific miRNA clusters 290 and 302 was tested 
in maGSCs derived from the following mouse strains: 129/Sv 
(maGSC 129SV), C57BL/6 (maGSC C57BL), FVB (maGSC FVB) 
and from the transgenic line Stra8-EGFP/ROSA26 (maGSC Stra8). 
All maGSC lines were cultured under standard ESC culture 
conditions. In addition, the expression of ESC specific miRNAs was 
studied in the teratocarcinoma cell line F9 (ECCs) which was found to 
share many similarities with pluripotent cells (Andrews, 2002). 
Finally, miRNA expression was tested in adult mouse testis.  
 
MEFs and NIH/3T3 cells served as negative controls, while ESCs 
derived from mouse strains 129/Sv (ESC R1) and Stra8-
EGFP/ROSA26 (ESC Stra8) were used as positive controls.  
 
To exclude the possibility that differences found in miRNA levels 
between different cell lines could be attributed to spontaneous 
differentiation of the cells due to improper culture conditions, 
pluripotent state was evaluated for all cell lines and tissues tested. 
Expression levels of Oct-4 and Sox-2 proteins, which are the most 
widely used markers for pluripotency, were evaluated with Western 
blotting.  
 
Both Oct-4 and Sox-2 were expressed in all maGSC, ESC and ECC 
lines tested (Fig. 4). Expression of Oct-4 was not detected in testis by 
Western blotting.  
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Figure 4. Expression of Oct-4 and Sox-2 proteins by Western blotting. The 
same membrane was used for both antibodies. a-Tubulin served as loading 
control. 
 
 
After the pluripotent state of the cells was confirmed, expression of 
the following members of miR-290 and miR-302 miRNA clusters was 
tested with quantitative reverse transcription PCR: 
 
 miR-290 family: miR-290_5p, miR-291_3p, miR-292_3p, miR-293, 
miR-294 and miR-295 
 miR-302 family: miR-302a, miR-302b and miR-302d 
 
This set of ESC-specific miRNAs was found to be expressed not only 
in ESCs but also in all maGSC lines tested as well as in F9 cells. No 
expression was detected in MEFs, NIH/3T3 cells and mouse testis 
(Fig. 5).  
 
Interestingly, miRNA expression pattern in maGSC Stra8 differed 
from maGSCs derived from other mouse strains by demonstrating 
lower and higher levels of miR-290 and miR-302 family, respectively. 
In addition, differences were observed between maGSC 129SV and 
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ESCs from the same mouse strain (ESC R1). In this case ESC R1 and 
maGSC 129SV were from different passage numbers. 
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Figure 5. Expression levels of ESC-specific miRNAs detected by Real-time 
PCR. Expression levels are normalized to the expression of the endogenous 
control (RNU6B). ESC R1 (of a different passage number of that used in all 
other experiments) was used as calibrator (cal). 
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3.4 Expression of miR-290 and miR-302 miRNA 
clusters in ESCs and maGSCs after culture for 
many passages and upon loss of pluripotency 
 
 
To exclude expression of these miRNAs only in maGSCs of early 
passage numbers, expression was tested also after culture for 10 
passages. To confirm that expression of these miRNAs is restricted 
only to undifferentiated maGSCs, lack of expression was tested in 
differentiated maGSCs after deprivation of LIF and induction with RA 
for 35 days (Gel+RA 35 days). maGSCs from the mouse strain 129/Sv 
were used. The respective ESC line from the same mouse strain (ESC 
R1) and of the same passage number was used as control.  
 
Pluripotent state of the cells was evaluated as reported above (Fig. 6). 
In addition, expression of SSEA-1, which is also a well known 
pluripotency marker, was tested by immunofluorescence (Fig. 7). 
Under standard ESC culture conditions maGSCs from the 129/Sv 
mouse strain express Oct-4 and Sox-2 at levels similar to those of the 
respective ESCs cultured for the same period of time and number of 
passages. In contrast, no expression of pluripotency markers was 
detected in differentiated ESCs and maGSCs, confirming that 
exposure for a long time to differentiation conditions  results in loss of 
pluripotency in both cell types. 
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Figure 6.  Expression of 
pluripotency markers in ESCs 
and maGSCs from 129/Sv 
background  after culture for 
35 days under standard ESC 
culture conditions (from 
passage 15 to passage 25) or 
in Gel+RA (0,1% gelatin
coated flasks without LIF but 
with RA). Levels of Oct-4
and Sox-2 proteins obtained 
by Western blotting were 
quantified densitometrically 
and normalized to levels of 
endogenous control (a-tub). 
Asterisks indicate statistical 
significance in comparison
with untreated cells. 
Cal=calibrator. 
Figure 7.  Immunostaining 
for SSEA-1 (Cy-3) in ESCs 
and maGSCs from 129/Sv 
background  under standard 
ESC culture conditions 
(untreated) and after culture 
for 35 days in Gel+RA
(0,1% gelatin coated flasks 
without LIF but with RA).
DAPI was used for staining 
of the nuclei. 
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Like ESCs, after culture for 10 passages under standard ESC culture 
conditions, maGSCs retain expression of the ESC-specific miRNAs 
(Fig. 8). However, these levels seem to vary between different passage 
numbers and independently cultured cells from the same cell line as 
shown in Appendix 3 and mentioned below (section 3.4.3.). 
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Figure 8. miRNA expression levels in ESC R1 and maGSC 129SV of passages 
15 and 25. Cal=calibrator. 
 
 
In addition, like in differentiated ESCs, loss of pluripotency in 
maGSCs resulted in hardly detectable expression levels of ESC-
specific miRNAs (Fig. 9). 
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Figure 9. miRNA expression levels in untreated ESC R1 and maGSC 129SV 
cells compared with the respective cells cultured for 35 days in Gel+RA (gelatin 
coated flasks without LIF but with RA). Asterisks indicate statistical 
significance. 
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3.5 Expression profiles of miR-290 and miR-302 
miRNA clusters during in vitro differentiation of 
pluripotent cells 
 
 
3.5.1 Differentiation strategy 
 
To induce differentiation of pluripotent cells in vitro, a number of 
factors are commonly used. Among them deprivation of LIF and 
addition of retinoic acid (RA) has been shown to be crucial for 
allowing and inducing differentiation. The effects of these factors on 
the expression of ESC-specific miRNA families 290 and 302 were 
examined in maGSCs in comparison to ESCs.  
 
Figure 10 summarizes the strategy that was followed. ESCs and 
maGSCs of passage P16 from the mouse strain 129/Sv (ESC R1 and 
maGSC 129SV, respectively) were cultivated for 5, 10 and 21 days 
under different culture conditions:  
 
 Feeder layer (FL), LIF and retinoic acid (FL+LIF+RA) 
 0.1% gelatin coated flasks (Gel) 
 0.1% gelatin coated flasks and retinoic acid (Gel+RA) or (Gel+RA 
from day 0) 
 Cells that were cultivated for 5 days in 0.1% gelatin coated flasks and 
then induced by retinoic acid for 5 days (Gel+RA from day 5) 
 
Cells were collected at day 5, 10 and 21 for further testing.  
 
To assess the degree of differentiation and loss of pluripotency of 
treated cells, levels of Oct-4 and Sox-2 were determined by Western 
analysis at the protein level or by qPCR at the mRNA level. 
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Then, expression of the following members of miR-290 and miR-302 
miRNA clusters was tested with quantitative reverse transcription 
PCR: 
 
 miR-290 family: miR-290_5p, miR-291_3p, miR-292_3p, miR-293, 
miR-294 and miR-295. 
 miR-302 family: miR-302a, miR-302b and miR-302d 
 
 
Untreated cells
(Feeder layer+LIF)
Differentiating Cells
Day 5 Day 21Day 10
ESC R1
maGSC
129SV
Differentiation 
conditions
Culture on 
Feeder Layer
(FL) with LIF
Culture in 
Gelatine(Gel)
coated flasks
Addition of 
Retinoic
Acid(RA)
Untreated
cells
 
 
 
 
Figure 10. Cell culture strategy for in vitro differentiation of ESCs and maGSCs 
from 129/Sv mouse strain (ESC R1 and maGSC 129SV). Cells were cultured for 
5, 10 and 21 days under the different culture conditions mentioned in the text. 
Deprivation of LIF and culture in gelatin coated flasks is depicted with blue 
colour, while addition of RA with red. Cells cultured for the same period under 
standard ESC conditions (yellow) were used as control (untreated cells). 
 
 
In case of F9 cells (ECCs), RA has been used in previous works 
(Alonso et al. 1991) to induce differentiation in these cells. Thus, in 
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order to induce differentiation, cells were treated with 10-6 M RA for 
25 days (Fig. 11). Then cells were tested for the above mentioned 
miRNAs and pluripotency markers. 
 
Untreated cells Differentiating Cells
(addition of RA)
Day 25
F9 
cells
 
 
Figure 11. Cell culture strategy for in vitro differentiation of ECCs (F9 cells). 
Cells were cultured for 25 days in the presence of RA (orange). Cells cultured 
for the same period under standard conditions (green) were used as control 
(untreated cells). 
 
 
3.5.2 Determination of loss of pluripotency in treated 
cells 
 
Figure 12 shows that, after five days under FL+LIF+RA condition, 
expression of Oct-4 and Sox-2 is strongly downregulated in ESCs and 
maGSCs. After culture of the cells for five days under Gel+RA 
condition, Oct-4 expression is hardly detectable in maGSCs and 
absent in ESCs. Furthermore, no Sox-2 expression is detected.  
 
However, culture under Gel condition for five days was found to 
result in downregulation of both pluripotency marker proteins only in 
ESCs, but not in maGSCs. In maGSCs, Oct-4 protein levels are 
similar to those of untreated cells. Only after cultivation of maGSCs 
under Gel condition for a longer period (21 days), Oct-4 expression is 
downregulated (Fig. 13). 
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Figure 12. Expression of Oct-4 and Sox-2 proteins by Western blotting in ESCs 
and maGSCs cultured for five days under the above mentioned conditions. 
Quantification of the blots was done by densitometry. Expression levels were 
compared between untreated and differentiating cells, asterisks indicate 
statistical significance. a-Tubulin served as loading control and for 
normalization of the values. Untreated  ESCs were used as calibrator. 
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Figure 13.  Expression of Oct-4
protein in untreated maGSCs 
(FL+LIF/calibrator) and in 
maGSCs under Gel condition over 
time (5, 10 and 21 days). 
Quantification of Western blotting 
results was done as described 
previously. One asterisk indicates 
statistical significance between 
day 5 and day 10, two asterisks 
between day 10 and day 21.  
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Figure 14. Expression of Oct-4 mRNA by Real-time PCR in ESCs and maGSCs 
cultured for 5, 10 and 21 days under all three differentiation conditions 
compared with untreated cells. Expression levels were normalized to 
endogenous control gene (Sdha) and calibrated to the levels of untreated ESC 
R1. 
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Evaluation of Oct-4 expression at the mRNA level confirmed the 
findings of Western blotting and revealed an upregulation of Oct-4 in 
ESCs under Gel condition at day 21 (Fig. 14). 
 
Also in case of F9 cells, downregulation of Oct-4 mRNA levels after 
treatment with RA for 25 days confirmed successful induction of 
differentiation for these cells (Fig.15). 
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Figure 15. Expression of Oct-4 mRNA by Real-time PCR in F9 cells treated 
with RA compared with untreated cells. Expression levels were normalized and 
calibrated as in Figure 14. 
 
 
3.5.3 Expression profile of miR-290 cluster during in 
vitro differentiation of ESCs and maGSCs 
 
Figure 16 shows the timeline expression profile of miRNAs of the 290 
miRNA cluster in ESCs and maGSCs under all differentiation 
conditions compared with untreated cells. Expression profiles where 
the different conditions for each miRNA are superimposed to facilitate 
their comparison are also presented in Appendix 3A. 
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Figure 16. Expression profiles of members of the miRNA 290 family in ESCs 
and maGSCs from mouse strain 129/Sv (ESC R1 and maGSC 129SV) under 
different differentiation conditions after 5, 10 and 21 days in culture compared 
with untreated cells.  All levels were normalized to endogenous control 
(RNU6B) and calibrated to the value of untreated ESC R1. For statistical 
significance of the observed differences see Appendix 4A. 
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In both ESCs and maGSCs, all members of the 290-family are 
constantly expressed or even increased in untreated cells, although in 
case of maGSCs at lower levels (50% of ESC expression in some 
cases) comparing with ESCs.  However, miRNA levels vary even 
between cells cultured under standard ESC conditions but for different 
periods of time (for example in case of miR-293 an increase in 
expression levels of more than 50% in untreated ESCs at day 21 
compared with untreated ESCs at day 5 is observed). 
 
In ESCs, these miRNAs are downregulated at day 5 of culture under 
all differentiation conditions with the strongest effect observed in 
Gel+RA condition. At day 10 and 21, miRNA levels can hardly be 
detected under all differentiation conditions.  
 
In maGSCs at day 5, levels of miRNAs do not decrease in Gel and 
Gel+RA conditions (with the exception of miR-290 in Gel+RA).  
Their expression is the same or even higher than in untreated cells. At 
day 10, miRNA levels have further increased under Gel condition 
(Fig.6b). In Gel+RA condition at day 10, miRNA levels do not 
increase further but they are still high, whereas a strong 
downregulation at day 10 is observed only under FL+LIF+RA 
condition. At day 21, miRNA levels of cells in Gel condition are 
lower than those of untreated cells (with the exception of miR-290), 
but remain still high in comparison to the other two conditions 
(Gel+RA and FL+LIF+RA), where miRNAs are hardly detectable. 
 
3.5.4 Expression profile of miR-302 cluster during in 
vitro differentiation of ESCs and maGSCs 
 
The expression profiles of members of the 302-cluster were found to 
differ significantly from those of miR-290 family members (Fig. 17, 
Appendix 3B).  
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Figure 17. Expression profiles of members of the miRNA 302 family in ESCs 
and maGSCs from mouse strain 129/Sv under different differentiation 
conditions after 5, 10 and 21 days in culture compared with untreated cells.  
Levels were normalized and calibrated as in Figure 16. For statistical 
significance of the observed differences see Appendix 4B. 
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In ESCs, the Gel condition has an extreme effect on the expression of 
miRNAs 302 at day 5. They become strongly upregulated (20-100 
fold increase). Their levels decrease rapidly after day 5, but even at 
days 10 and 21 of culture, the miRNA expression is still higher than in 
untreated cells. In Gel+RA, miRNA levels increase temporally to 
levels higher than in untreated cells around day 10.  Then they 
decrease leading to expression levels lower than in untreated cells at 
day 21. miRNAs 302 become also upregulated in maGSCs under Gel 
condition. During the culture period of 21 days, expression levels 
increase 10-30 fold. However, in case of maGSCs, levels increase 
gradually at least until day 21, and not only at day 5 like in ESCs.  
 
In the other two conditions (Gel+RA and FL+LIF+RA) miRNA levels 
at day 5 are higher than those in untreated cells and become similar to 
them thereafter.  
 
 
3.5.5 Expression profile of miR-290 and miR-302 
clusters during differentiation of ECCs 
 
When ECCs are treated with 10-6 M RA for 25 days, miR-290 and 
miR-291 levels decrease slightly, miR-292, miR-293 and miR-294 
levels remain relatively stable and only miR-295 increases. In 
contrast, levels of all miR-302 family members increase significantly 
(3-5 fold increase) (Fig. 18). 
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Figure 18. Expression profiles of members of miRNA families 290 and 302 in 
untreated F9 cells and in those treated with RA for 25 days. All levels were 
calibrated to the value of untreated ESC R1 (FL+LIF) at day 5.  Asterisk depicts 
statistical significance. 
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3.6 Determination of the differentiation state of the 
cells tested 
 
 
In ESCs, there is a body of citable evidence that provides a precedent 
for using these methods to differentiate ESCs in vitro. To test whether 
maGSCs achieve like ESCs multilineage differentiation in the 
differentiation system employed in this study, differentiation into 
three germ layers was tested. This was performed by analyzing the 
time-course and extent of differentiation marker expression in the 
maGSCs cultured under the various conditions. Expression of the 
following differentiation markers was tested with qPCR: 
 
 Nestin (for ectoderm) 
( Lendahl, 1997; Lin et al., 1995; Wiese et al., 2004) 
 Brachyury (for mesoderm) 
(Showell et al., 2003) 
 Hnf-4 (for endoderm)  
(Duncan et al., 1997; Taraviras et al., 1994) 
 Nkx-2.5 (for early embryo heart formation) 
(Liberatore et al., 2002)  
 
Expression levels in the respective ESCs were also evaluated for 
control and comparison with maGSCs. For statistical significance of 
the observed differences (with the exception of Brachyury, where all 
differences were statistical significant when it was expressed) see 
Appendix 5. 
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3.6.1 Ectoderm formation: Nestin 
 
maGSCs differentiate towards ectoderm later than ESCs, with the 
exception of FL+LIF+RA condition, where only maGSCs express 
Nestin in higher levels compared with untreated cells (Fig. 19). 
 
 
3.6.2 Mesoderm formation: Brachyury 
 
No Brachyury expression was observed in both cell types when RA 
was added. Under Gel condition ESCs express Brachyury at high 
levels at day 5 and then again at day 21. In contrast, maGSCs express 
Brachyury later than ESCs, at day 21 and in lower levels (Fig. 20). 
  
 
3.6.3 Endoderm formation: Hnf-4 
 
Undifferentiated maGSCs express Hnf-4 at higher levels than 
undifferentiated ESCs. In both cell types upregulation applies to 
conditions where RA is added. In contrast to maGSCs, in ESCs 
upregulation occurs only transiently at day 5 and at lower levels (Fig. 
21). 
 
 
3.6.4 Early embryo heart formation: Nkx-2.5 
 
In ESCs upregulation occurs mainly under Gel+RA condition and 
under Gel condition at day 21. In maGSCs upregulation occurs only 
under Gel condition after day 5 at similar levels with ESCs (Fig. 22). 
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 Figure 19. Expression of Nestin mRNA by Real-time PCR in ESCs and maGSCs 
cultured for 5, 10 and 21 days under all three differentiation conditions compared 
with untreated cells. Expression levels were normalized to endogenous control 
gene (Sdha) and calibrated to the levels of untreated ESC R1. 
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 Figure 20. Expression of Brachyury mRNA by Real-time PCR in ESCs and 
maGSCs cultured for 5, 10 and 21 days under all three differentiation conditions
compared with untreated cells. Expression levels were normalized and calibrated 
as in Figure 19. 
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 Figure 21. Expression of Hnf-4 mRNA by Real-time PCR in ESCs and maGSCs 
cultured for 5, 10 and 21 days under all three differentiation conditions compared 
with untreated cells. Expression levels were normalized and calibrated as in 
Figure 19. 
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Figure 22. Expression of Nkx-2.5 mRNA by Real-time PCR in ESCs and 
maGSCs cultured for 5, 10 and 21 days under all three differentiation conditions
compared with untreated cells. Expression levels were normalized and calibrated 
as in Figure 19. 
Results                                                                                                           83  
       
___________________________________________________________________________ 
3.6.5 Differentiation state of treated F9 cells 
 
Differentiation of F9 cells treated with RA was characterized by an 
increase in Nestin and Hnf-4 expression (Fig. 23), while no expression 
was detected for Brachyury (data not shown). 
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Figure 23. Expression of Nestin and Hnf-4 in untreated and treated with RA F9 
cells. Asterisk depicts statistical significance. Expression levels were normalized 
and calibrated as in Figure 19. 
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3.7 Correlation of the differentiation state of the cells 
with miRNA levels of miR-290 and miR-302 
clusters. 
 
 
In order to identify a possible connection between expression levels of 
miRNAs tested and differentiation state, differences in miRNA levels 
between the different cell types and different conditions tested were 
correlated with differences in the expression of pluripotency and 
differentiation markers. Based on these comparisons the following 
correlations were found: 
 
 
3.7.1 Correlation of miR-302 with Brachyury 
expression 
 
Figure 24 shows that in both ESCs and maGSCs, changes in the 
miRNA levels of miR-302 family follow the same pattern as changes 
in the Brachyury expression. 
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Figure 24. Relative expression levels (qPCR) of miR-302a (up) and Brachyury 
(down) in ESC R1 (left) and maGSC 129SV (right). A significant increase in 
Brachyury and miR-302 expression  is observed  (in both cell types) only in Gel 
condition 
  
 
3.7.2 Correlation of miR-290 with Oct-4 expression 
(based on differences between different 
conditions) 
 
In both ESCs and maGSCs, higher levels in miR-290 cluster levels 
under Gel condition compared with the other two conditions are 
connected with also higher  levels of Oct-4 under this condition (Fig. 
25). 
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Figure 25. Relative expression levels (qPCR) of miR-290 (up) and Oct-4 
(down) in ESC R1 (left) and maGSC 129SV (right). High levels in Oct-4 and 
miR-290 expression  are observed  (in both cell types) only under Gel condition. 
 
 
3.7.3 Correlation of miR-290 with Oct-4 expression 
and differentiation (based on differences between 
different cell types) 
 
 
Under Gel  and/or Gel+RA condition, Nestin and Brachyury become 
upregulated earlier in ESCs as compared with maGSCs, while the 
opposite characterizes Oct-4 and miR-290 cluster expression, which in 
maGSCs decrease later than in ESCs (Figs. 12, 16, 19 and 20).   
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3.7.4 Time dependent influence of RA during ESC and 
maGSC differentiation 
 
 
Effects of RA on differentiation have been shown to be time 
dependent. Thus, miRNA and differentiation markers expression 
levels at day 10 were compared between Gel+RA (or Gel+RA from 
day 0) condition (where RA was added from the beginning of 
differentiation) and Gel+RA from day 5 (where RA was added from 
day 5 of differentiation onwards).  
 
In maGSCs, if RA is added from day 5 onwards (Gel+RA from day 
5), 290 miRNA family levels at day 10 are lower as compared with 
Gel+RA condition (Fig. 26). In addition, the increase from day 5 to 
day 10 observed in maGSCs under Gel for miR-302 family is 
minimized when RA is added from day 5 onwards (Gel+RA from day 
5), but miRNA levels in this condition are still higher as compared 
with Gel+RA at the same day (Fig. 27). 
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Figure 26. miR-291 expression levels at day 5(1), 10(2) and 21(3) under the 
three differentiation conditions mentioned in the text. Similar patterns were 
observed for the other members of miR-290 cluster and are presented in 
Appendix 3A). 
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Figure 27. miR-302b expression levels at day 5(1), 10(2) and 21(3) under the 
three differentiation conditions mentioned in the text. Similar patterns were 
observed for the other members of miR-302 cluster and are presented in 
Appendix 3B). 
 
Finally, in ESCs, miRNA levels of 302 cluster under Gel+RA from 
day 5 condition are significantly lower than Gel+RA from day 0 
condition (Fig. 28). 
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Figure 28  
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Figure 28. Comparison of expression levels of members of miRNAs and 
differentiation markers at day 10 in ESCs and maGSCs from mouse strain 
129/Sv (ESC R1 and maGSC 129SV) between Gel+RA (cells cultured in Gel 
coated flasks with addition of RA from the beginning) and Gel+RA from day 5 
(cells cultured in Gel coated flasks with addition of RA from day 5) conditions. 
The line that cuts the diagram in two parts, separates ESCs (left) from maGSCs 
(right). All miRNA and mRNA levels were normalised to endogenous control 
(RNU6B and Sdha respectively) and calibrated to the value of untreated ESC R1 
(FL+LIF) at day 5. Asterisk indicates statistical significance comparing with Gel  
+RA from day 0 condition. # indicates no statistical significance (a) Expression 
levels of miR-290 family. (b) Expression levels of miR-302 family. (c) 
Expression levels of Vimentin, Nestin, Hnf-4 and Nkx-2.5 
 
 
Concerning differentiation markers, Vimentin, a marker expressed  
early during gastrulation, was also tested (Boisseau and Simonneau 
1989; Colucci-Guyon et al. 1999; Franke et al. 1982). Compared with 
Gel+RA condition, levels of Nestin and Vimentin in ESCs were lower 
when RA was added from day 5, while in maGSCs Nestin, Vimentin 
and Nkx-2.5 were increased under this condition and only Hnf-4 
levels were lower (Fig. 28). 
 
In general, when Gel+RA and Gel+RA from day 5 conditions are 
compared, high levels of miR-290 family are connected with low 
levels of miR-302 family and most of differentiation markers (with the 
exception of Hnf-4) and vice versa. 
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3.8 Determination of de novo DNA 
methyltransferases expression profile in ESCs 
and maGSCs 
 
 
De novo DNA methyltransferases 3A and 3B (Dnmt3A and 3B) have 
been shown recently to be regulated by miRNAs of the 290 cluster by 
controlling an inhibitor of their transcription, Rbl protein. In order to 
test whether differences in 290 miRNA expression profile between 
ESCs and maGSCs during differentiation affect expression of Dnmts, 
their levels were determined during in vitro differentiation of both cell 
types. 
 
As shown in Figure 29, expression profile of Dnmt3A differed 
between ESCs and maGSCs in all three differentiation conditions. 
Levels of Dnmt3A in maGSCs are downregulated during 
differentiation, while in ESCs DNMT3A is upregulated under Gel and 
Gel+RA condition. In contrast Dnmt3B showed a similar expression 
pattern between the two cell types (Fig. 30). 
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Figure 29. Expression of Dnmt3A mRNA by Real-time PCR in ESCs and 
maGSCs cultured for 5, 10 and 21 days under all three differentiation conditions
compared with untreated cells. Expression levels were normalized and calibrated 
as in Figure 19. 
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 Figure 30. Expression of Dnmt3B mRNA by Real-time PCR in ESCs and 
maGSCs cultured for 5, 10 and 21 days under all three differentiation conditions
compared with untreated cells. Expression levels were normalized and calibrated 
as in Figure 19. 
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4.   Discussion 
 
 
Understanding the molecular basis of pluripotency in maGSCs will 
greatly benefit the field of stem cell biology by providing new 
pathways and mechanisms that could increase the yield of maGSCs 
and allow their derivation also in human for regenerative medicine 
purposes.  
 
Efforts to better integrate the transcriptional and epigenomic networks 
that control pluripotency in maGSCs are in progress (Meyer 2008; 
Zechner 2008), and will help to identify the specific mechanisms 
required for maintenance of pluripotency in maGSCs which until now 
remain elusive. However, one potential regulatory mechanism that has 
until now received little attention in ESCs and maGSCs is miRNAs.  
 
Aim of this study was to provide for the first time a comprehensive 
view of the whole microRNAome of maGSCs compared with that of 
ESCs. To this end, whole microRNA array expression profiling of 
maGSCs from two different mouse strains and the respective ESC 
lines was performed. The array experiments and the subsequent 
confirmation of the results with qPCR revealed almost an identical 
miRNA expression profile between ESCs and maGSCs of 129/Sv 
background, but a distinct miRNA signature of maGSCs derived by 
the Stra8 transgenic mouse (maGSC Stra8).  
Next, this study focused further to all these miRNAs that has been 
until now annotated a unique role in embryonic stem cell physiology 
(miR-290 and -302 clusters). To this end, this study compared 
expression of these miRNAs as well as of protein markers of 
pluripotency in ESCs and maGSCs under normal and differentiating 
culture conditions. It was demonstrated by Western blotting that the 
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stem cell markers Oct-4 and Sox-2 are present in multiple maGSC 
lines, as it is known for ESCs. Then, it was demonstrated that 
miRNAs of the miR-290 and miR-302 family are present in maGSCs, 
as previously reported for ESCs.   
Using standard methods to induce ESC differentiation (e.g., culture in 
the presence of gelatin and/or retinoic acid), this study showed loss of 
stem cell markers and miR-290 family expression in ESCs. Likewise, 
maGSC cultures lost pluripotent marker expression and miR-290 
family expression was strongly attenuated, albeit slower than in ESCs. 
maGSC cultures responded different to differentiation with gelatin 
than ESCs, resulting in sustained Oct-4 expression and transient miR-
290 family upregulation. This study also demonstrated that ESC 
differentiation with gelatin led to a marked and early upregulation of 
the miR-302 family that was lost over time, which differed with the 
slow and steady upregulation observed in maGSCs treated similarly.   
Consistent with pluripotent marker expression profile, expression 
levels of most differentiation markers in maGSCs increased later than 
in ESCs, while both cell types differed as far as expression pattern of 
de novo DNA methyltransferases is concerned.  
Lastly, this study demonstrated miR-290 and miR-302 expression in 
the pluripotent F9 embryonic carcinoma cell line and correlated their 
expression under differentiation conditions with stem cell and 
differentiation markers.   
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4.1   The metazoan microRNAomes and the 
importance of miRNA-mediated regulation of 
gene expression 
 
 
The existence of very small non-coding RNAs (about 21 nt) in 
eukaryotes is already known for many years and was believed to be 
result of degradation procedures of bigger RNA molecules in cells. 
Only in the last decade it became obvious that these RNA molecules, 
called microRNAs, mediate specific cellular processes in cells, 
playing a key role in cell physiology (Lagos-Quintana et al. 2001; 
Lagos-Quintana et al. 2002).  
 
Frequently referred to as ‘micromanagers of gene expression’, 
miRNAs were first described to regulate developmental timing in 
C.elegans (Bartel 2004). Since then attempts have been made to 
elucidate the pathways that govern the biogenesis of these small non 
coding RNAs. Most miRNAs are located in intergenic regions (like 
miR-290 and miR-302 families), although some miRNAs are found in 
the intronic regions of known genes (like oncomirs) (Mendell 2008; 
miRBase). miRNA genes can be transcribed from their own promoters 
producing a primary transcript called pri-miRNA, although regulation 
by the host gene can not be excluded for intergenic located miRNAs. 
Transcription is mainly mediated by RNA polymerase II and pri-
miRNAs were shown to contain both cap structures and poly(A) tails. 
In addition, ~50% of miRNAs are found in close proximity to other 
miRNAs, and were proved or postulated to be transcribed from a 
single polycistronic pri-miRNA (miRNA clusters), indicating that 
these miRNAs are co-ordinately regulated during development (Kim 
2005). This is further supported in this study, since expression profile 
of miRNAs belonging to the same family showed identical expression 
patterns. 
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The widespread presence of miRNAs in metazoan genomes reflects 
the ubiquitous association of miRNAomes with global gene regulatory 
networks in cells and numerous publications have revealed their 
importance in development as well as in disease: miR-430 has been 
shown to control maternal-zygotic transition in zebrafish. Dicer 
knockout mice, which means no miRNA biogenesis, die in early 
embryogenesis (Chen K and Rajewsky 2007; Kanellopoulou et al. 
2005). In humans, miRNA disruption has been described in 
association with several cancers, while miRNAs were also connected 
with pathogenesis of Fragile X and Di George syndromes (Kim 2005; 
Mendell 2008). In addition, recently microRNAs targeting Nanog, 
Oct-4 and Sox-2 in their coding regions have been shown to modulate 
embryonic stem cell differentiation (Tay et al. 2008). And these are 
only some examples of experimentally validated miRNA functions. 
 
But why are miRNAs so important for gene expression? Although the 
importance of transcription as the necessary first step in expression of 
genes cannot be denied, this does not mean that transcription has 
always the largest impact on the final concentration of the active gene 
product. By repressing translation of mRNAs, miRNAs can have a 
large effect on this concentration, which is the most relevant quantity 
to the phenotype.  
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4.2    Large scale analysis of maGSCs` microRNAome 
 
 
The first works that quantified the genome wide expression of 
miRNAs in mouse ESCs compared with differentiating cells and adult 
tissues were those of Chen C et al. (2007) and Strauss et al. (2006) and 
showed a distinct expression signature of miRNAs in ESCs. Results 
were similar to those performed in human ESCs by other groups like 
Suh et al. (2004) and Laurent et al. (2008). 
 
Results presented in this study show that maGSCs derived from SSCs 
of a 129/Sv background share this unique miRNA signature with 
ESCs. From all miRNAs tested by global miRNA array expression 
profiling only two miRNAs (miR-19b and miR-20b) showed 
differential expression between ESCs and maGSCs in both biological 
replicates tested. These miRNAs belong to a group of miRNAs called 
oncomirs. This group consists of miR-17-92 cluster and its paralogues 
(Fig. 31) and has been annotated a key role in cell proliferation and 
carcinogenesis (Mendell 2008), and as discussed later also in germ 
cell development. Although oncomirs do not belong to the same 
miRNA clusters as ESC-specific miRNAs (miR-290 and miR-302 
families), many of the oncomirs are predicted by computational 
methods to share the same mRNA targets with ESC-specific miRNAs. 
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           (Source, Mendell 2008, p.218) 
 
Figure 31.  Genomic organization of miR-17-92, miR-106a-363 and miR-106b-
25 miRNA clusters and structures of the respective pri-miRNAs. The last two 
miRNA clusters are paralogues of the first. miRNAs of all three clusters belong 
to oncomirs. 
 
However, confirmation of these data with qPCR revealed that these 
differences between ESCs and maGSCs are restricted to cells 
originating from a 129/Sv mouse background only. 
 
Thus, it can be concluded that concerning microRNAome, ESCs and 
maGSCs of 129/Sv background present almost the same expression 
signature which is consistent with their similar gene expression and 
imprinting profile found elsewhere (Meyer 2008; Zechner 2008). 
Furthermore, most of the observed differences between ESC Stra8 and 
ESCs and maGSCs from 129/Sv mouse should be attributed to the 
different genetic background of ESC Stra8, since they were not found 
to be present in ESCs and maGSCs from the same mouse strain. 
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In contrast maGSC Stra8 cells showed a distinct miRNA expression 
profile from all other cell lines. As discussed later such differences 
were also confirmed when expression of miR-290 and miR-302 
clusters was tested. These results were further correlated with global 
genome expression profiling and imprinting studies of the same cells. 
Global genome expression profiling revealed a distinct mRNA 
expression signature for maGSC Stra8 compared with all other ESC 
and maGSC lines tested that clustered together. Interestingly, maGSC 
Stra8 cells expressed germ cell markers like Dppa3 and Stra8 in 
higher levels than other cell lines. Imprinting studies resulted in 
similar conclusions.  
 
All these results suggest that maGSCs derived from the transgenic 
mouse are a distinct pluripotent cell line, compared with all other ESC 
or maGSC lines. 
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4.3  Expression analysis of ESC-specific miRNAs in 
maGSCs, ECCs and testis 
 
 
In 2003, the Sharp group  was the first to identify and describe the 
ESC specific miR-290 cluster in mouse (Fig. 32) (Houbaviy et al. 
2003; Houbaviy et al. 2005), while later the set of ESC specific 
miRNAs in mouse included also members of the miR-302 cluster 
(Chen C et al. 2007; Strauss et al. 2006). These miRNAs were found 
to be specifically expressed in ESCs and downregulated during 
differentiation of ESCs into Embryoid Bodies (EBs), while no 
expression was reported for adult tissues. In addition, these miRNA 
families have human homologues that have similar genomic 
organization and expression patterns, suggesting that they may operate 
as key regulatory networks conserved in mammalian pluripotent stem 
cells (Suh et al. 2004).  
 
(Source: Houbaviy et al. 2003, p.354) 
 
Figure 32.  Genomic organization and structure of miR-290 cluster. Sequences 
marked in red represent the mature miRNA sequences. 
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This study provides evidence that these miRNAs characterize 
generally pluripotency, since they were detected not only in ESCs but 
also in all maGSC and ECC lines tested. In contrast, as expected, no 
expression was detected in non pluripotent cells. Expression of these 
miRNAs in maGSCs is not restricted to cells of early passage 
numbers, but remained even after culture for many passages (Fig. 8). 
However, in contrast to F9 cells, proliferation and expression of these 
markers in maGSCs is restricted to standard ESC culture conditions, 
implying  that, like in ESCs, expression of these miRNAs is connected 
with their pluripotent state. This is an important similarity between 
ESCs and maGSCs that distinguishes them from ECCs and suggests 
similar underlying mechanisms controlling pluripotency between 
maGSCs and ESCs. 
 
However, expression levels differed between some maGSCs from 
different mouse strains, as well as between some ESCs and maGSCs 
from the same mouse strain. A possible explanation for this, apart 
from the different genetic background, could be the different passage 
number of the cell lines tested. As shown in figures of Appendix 4, 
even under standard ESC culture conditions miRNA expression levels 
vary between different passage numbers (which for example in case of 
miR-293 demonstrates an increase in expression levels of more than 
50% in untreated ESCs at day 21, Figure c of Appendix 4A, compared 
with untreated ESCs at day 5, Figure a of Appendix 4A).  
 
For this reason in all other experiments, cell lines of the same passage 
number and the same mouse strain (129/Sv) were used to eliminate 
this effect. In this case, when cell lines of the same passage number 
are used, maGSCs 129SV seem to express these miRNAs in similar or 
slightly lower levels than ESCs from the same background (ESC R1).  
 
Finally, the great heterogeneity reported by previous groups in ESC 
cultures (Houbaviy et al. 2003), which is due to stochastic or difficult 
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to control factors (like serum batch, medium age, frequency of 
subculture etc), should always be taken into account when trying to 
explain the differences observed in gene and microRNA expression. 
In this study, these factors were eliminated to the most possible extent 
by two ways: Firstly, by the use of biological duplicates where 
possible and applicable. Secondly by constant evaluation of the 
pluripotent state of the cells tested, to exclude that differences in 
miRNA levels should be attributed to improper culture conditions or 
spontaneous differentiation of the cells. 
 
The fact that quantification of these miRNAs in testis revealed no 
relative expression as compared with ESCs and maGSCs does not 
exclude the existence of these miRNAs in SSCs in adult testis. In fact 
a recent work (Hayashi et al. 2008) reported that miRNA 290 cluster 
together with miR-17-92 cluster are highly expressed in PGCs and 
spermatogonia and that miRNA biogenesis is essential for their 
development, and even in the current study these miRNAs were 
detectable with RT-PCR in adult testis (data not shown). Similarly, no 
Oct-4 was detected in the testis sample although previous reports 
demonstrate Oct-4 immunoreactivity by histochemical methods from 
embryonic through adult testes (He Z et al. 2007).  These results could 
be attributed to the fact that spermatogonial stem cells constitute only 
0.03% of all germ cells (Tegelenbosch and de Rooji 1993) making it 
difficult  to detect Oct-4 by Western analysis. For this reason, 
compared with maGSCs, the normalized Real-time PCR data for 
miRNAs from the whole testis would be also practically zero. 
However, whether these miRNAs really exist in adult SSCs, and 
which functional implications this has for their differentiation 
potential remains to be elucidated.   
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4.4    Expression profile during differentiation 
 
 
A second major goal of this work was to examine the effects of 
different factors that are commonly used for in vitro differentiation of 
pluripotent cells on the expression of members of ESC-specific 
miRNA families. Since the great importance of ESCs and maGSCs 
lies on their regenerative potential in medicine, understanding the 
underlying mechanisms of their differentiation in vitro, requires again 
a substantial knowledge about their transcriptional, epigenetic and 
miRNA expression profile during this process.  
 
Three general approaches have been employed to initiate in vitro 
differentiation of pluripotent cells (Keller 2005). With the first method 
cells are allowed to aggregate and form three dimensional colonies 
(embryoid bodies). In the second, cells are cultured directly on stromal 
cells, and in the third cells differentiate in a monolayer (Nishikawa et 
al. 1998). This last approach can minimize the influence of 
neighboring cells and supportive stromal cells to the results and in this 
regard it was used as one of the simplest methods in this study.  
 
In addition, due to the big number of differentiation strategies so far 
described in the literature, this study concentrated on the most 
important factors that prevent or induce differentiation in ESC culture, 
namely LIF and RA. It is well known that the signaling pathway 
mediated by LIF (LIF-STAT3) is, together with that mediated by Oct-
4, critical for self-renewal of mESCs and maintenance of feeder-free 
ESC lines (Liu et al. 2007; Rao 2004; Kurosawa 2007). Furthermore, 
RA has been found to negatively regulate Oct-4 and to induce 
differentiation of ESCs and ECCs (Rohwedel et al. 1999; Tighe and 
Gudas 2004). 
 
Discussion                                                                                                             105  
       
___________________________________________________________________________ 
4.4.1  Members of miR-290 family are connected with 
maintenance of pluripotency 
 
The observation of other authors that the members of miRNA family 
290 are downregulated in ESCs during differentiation is supported by  
this study and a downregulation was found to be realized during 
maGSCs differentiation. However, in maGSCs under Gel and Gel+RA 
condition, miRNA levels remain high for a longer period than in ESCs 
or even increase transiently (Gel condition). These differences seem to 
correlate with the differences in the differentiation status of these 
cells. Under Gel condition, Nestin and Vimentin are upregulated 
earlier in ESCs, while Oct-4 expression decreases later in maGSCs. In 
addition, FL+LIF+RA, which is the only condition in maGSCs at day 
10 with a significant increase in most differentiation markers, is 
characterized by a strong downregulation of miRNA levels.   
 
Since the expression profile of Oct-4 corresponds to that of members 
of miRNA family 290 in both ESCs and maGSCs, our results indicate 
that expression of these miRNAs is more connected with maintenance 
of pluripotency than with differentiation. 
 
 
4.4.2   Members of miR-302 family are induced during 
first stages of in vitro differentiation 
 
Chen C et al. (2007) have studied expression of members of the 
miRNA 302 family in ESCs at days 3, 6 and 9 during embryoid body 
formation in absence of LIF. They found that these miRNAs are 
negatively correlated to differentiation time. This expression profile in 
ESCs is different from that it was  obtained in this study, since during 
the first five days of differentiation under Gel condition, all members 
of miRNA family 302 are strongly upregulated. Transient 
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upregulation of these miRNAs in ESCs is also observed in the 
presence of RA, although not so strongly as in Gel condition.  
 
Expression profiles of these miRNAs in maGSCs demonstrate 
similarities and differences compared with ESCs. Under Gel 
condition, strong upregulation of miRNA levels is also observed, and 
addition of RA was found to result also in an upregulation of these 
miRNAs. However, in maGSCs upregulation under Gel condition 
takes place slowly. At day 21 miRNA levels in maGSCs depict 10-30 
fold increase, while in ESCs 20-100 fold increase is reached already at 
day 5. This gradual increase in maGSCs correlates to the differences 
in differentiation status between ESCs and maGSCs mentioned above. 
In addition, the increase under Gel+RA condition in maGSCs occurs 
at day 5 and not at day 10 as in ESCs. 
 
Since the expression profile of Oct-4 does not correspond to that of 
302 miR-family members, our results suggest that these miRNAs may 
be more connected with response of pluripotent cells to differentiation 
than with the undifferentiated state itself.  
 
This is in contradiction to the observation that, even in 
undifferentiated cells, miRNAs 302 are present but can be explained 
by the observation that cultures of pluripotent cells contain 
spontaneously differentiated cells (Houbaviy et al. 2003). It is not yet 
clear the reason why the group of C. Chen did not observe this 
transient upregulation of miR-302 family during differentiation. 
 
 
4.4.3   Further proofs about connection of these 
miRNAs with pluripotency or differentiation 
 
The connection of members of miRNA family 290 with pluripotency 
and that of members of miRNA family 302 with the process of 
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differentiation is further supported by miRNA analysis in ECCs and 
comparison at day 10 of Gel+RA condition with Gel+RA from day 5.   
 
In ECCs, where addition of RA is followed by an increase in Nestin 
and Hnf-4 expression, miR-302 family is upregulated. Similarly, when 
Gel+RA and Gel+RA from day 5 conditions are compared, high levels 
of miR-290 family are connected with low levels of miR-302 family 
and most of differentiation markers (with the exception of Hnf-4) and 
vice versa.  
 
This connection is also supported by the findings of Tang et al. 
(2007). They have shown that the miRNA 290 family belongs to the 
most significant miRNAs strongly upregulated in early mouse 
embryogenesis from two-cell stage onwards. This is exactly the stage 
when Oct-4 expression increases (Schoeler et al. 1989). In contrast, 
miRNA family 302 does not show significant expression changes.  
 
 
4.4.4   miRNAs and mesoderm formation 
 
An interesting finding of this work is that the extreme upregulation of 
miR-302 family under Gel condition is connected with a 
predominantly mesoderm character of these cells (only under this 
condition, expression of Brachyury was observed). Differentiation to 
mesoderm requires Bmp-4 signaling and serum used in the ESC 
medium is known to be able to induce similar activities. However, at 
the moment it remains unclear whether these miRNAs have a positive 
or a negative effect on this process. It is possible that these miRNAs 
target an inhibitor of this pathway resulting in increased Brachyury 
expression. However, since after day 5 both levels of Brachyury and 
miRNAs 302 decrease dramatically, it can not be excluded that this 
decrease is due to these miRNAs, that may target an important 
pathway mediator. This is further supported by the observation of 
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Alisch et al. (2007) that reported ectopic expression of Brachyury in 
mouse embryos with impaired Argonaute 2 function, which is 
essential for miRNA mediated translational silencing. 
 
In fact, computational approaches that predict possible mRNA targets 
for different miRNAs (TARGETSCAN software) revealed that 
miRNAs of miR-302 family (and miR-290 family also) can target 
both activators and inhibitors of the Bmp-4 pathway (Table 4). This 
applies also to other pathways (Wnt pathway, Nodal signaling) that 
like Bmp-4 are involved in mesoderm formation and germ cell 
development (for a comprehensive review about all the above 
mentioned pathways see Tam and Loebel 2007). 
 
 
mRNA target Pathway Action Targeting 
miRNAs 
Tob1 Bmp-4 Inhibitor 292_3p 
Tob2 Bmp-4 Inhibitor 294, 295, 302, 
291_3p 
Lefty 1 and 
Lefty2 
Nodal Inhibitor 294, 295, 302, 
291_3p 
Dkk1 Wnt Inhibitor 294, 295, 302, 
291_3p 
Smad 1 Bmp-4 Activator 291_5p 
Smad 2 Nodal Activator 294, 295, 302, 
291_3p 
Smad 5 Bmp-4 Activator 291_5p 
 
Table 4. Computational prediction of targeting miRNAs for genes mediating 
Bmp-4, Wnt and Nodal pathways. Prediction was performed using the 
TARGETSCAN software available on line. Only miRNAs belonging to miR-
290 or miR-302 families and with binding sites at 3` UTR of these genes that 
were  conserved in both human and mouse are presented. 
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For these reason, functional studies that would overexpress these 
miRNAs are necessary for elucidation of their roles in these processes. 
 
 
4.4.5   miRNAs and germ cell development 
 
Another interesting finding of this in vitro differentiation study is 
some differences -compared with ESCs- in the expression profile of 
maGSCs regarding pluripotency markers and miRNAs. In particular, 
maGSCs proved to be more resistant in loss of pluripotency upon 
deprivation of LIF than ESCs. The same pattern was realized for 
miRNAs of 290 family, while in contrast, miR-302 family (which 
from this study was shown to correlate with beginning of 
differentiation) is upregulated later in these cells. This profile is in 
agreement with the profile mentioned earlier for PGCs, where cells 
were mainly enriched in miR-290 family and in the oncomirs, but not 
in miR-302 (Hayashi et al. 2008). Thus, it can not be excluded that 
maGSCs under Gel condition represent an equivalent cell type of 
PGCs.  
 
To test this, our group has further evaluated expression of Dppa3, 
which is the most representative PGC marker (Lacham-Kaplan 2004), 
in the same differentiating cells employed in this study (A. Pantazi, 
unpublished work). The results (Fig. 33) confirm this hypothesis, 
since maGSCs under Gel condition express Dppa3 in significantly 
higher levels than ESCs. Taking into account that Bmp-4 pathway, 
that may be regulated by miR-302 family, is necessary for PGC 
development and spermatogenesis (Itman and Loveland 2008), 
possible functional implications of this family in germ cell 
development should be tested in the future. 
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Figure 33.  Dppa-3 mRNA expression in ESC R1 and maGSC 129SV during 
differentiation. A: Gel, B: Gel+RA, C: FL+LIF+RA. Dppa 3 is predominantly 
expressed in undifferentiated maGSCs and in maGSCs under Gel condition 
compared with ESCs. Results are presented as normalized relative expression 
levels.  ESC R1 at day 0 was used as calibrator. 
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4.5  miRNAs and de novo DNA methylation in 
maGSCs 
 
 
Until now, little is known about the exact function and role of these 
miRNAs in pluripotency and development. Most studies have 
achieved a global miRNA “knock out” by targeting Dicer which is 
indispensable for miRNA maturation. These studies revealed that 
Dicer KO mice embryos are lethal and Dicer-KO ESCs presented 
differentiation defects (Kanellopoulou et al. 2005). The reason for this 
was partially explained by the results of a recent study that showed 
that miRNAs of miR-290 family control de novo DNA methylation by 
targeting Rbl2, which is an inhibitor of Dnmt3A and Dnmt3B 
transcription (Sinkkonen et al. 2008). These methyltransferases are 
responsible for de novo DNA methylation during differentiation of 
pluripotent cells.  
 
Since maGSCs presented differences in the expression profile of these 
miRNAs compared with ESCs it was challenging to test them for 
expression of DNMT3A and B in the differentiation model employed 
in this study. Our results revealed that the different miRNA expression 
profile of maGSCs corresponds to a different expression pattern for 
DNMT3A. In light of recent findings showing a significant decrease 
in global DNA methylation of maGSCs during differentiation 
compared with ESCs (Zechner 2008), these results support further the 
hypothesis that differentiating maGSCs are an equivalent type of 
PGCs, which during differentiation show a similar global DNA 
demethylation (Fig. 34). It is reasonable to suggest that this decrease 
in DNA methylation in maGSCs could be attributed to the low levels 
of DNMT3A in these cells during differentiation. Since Sinkkonen et 
al. (2008) performed their experiments mainly in Dicer KO cells, 
additional studies that will specifically downregulate these miRNAs in 
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pluripotent cells are needed to solidify also the relationship between 
these miRNAs and de novo DNA methylation in maGSCs.  
 
 
 
 
 
(Source: Reik et al. 2001, p.1090) 
 
Figure 34. Global DNA methylation profile of PGCs during development 
towards male or female gametes. PGCs show a transient global loss of 
methylation prior to differentiation into germ stem cells. 
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4.6    Conclusions and Perspectives 
 
 
Derivation of pluripotent cells and their differentiation into specific 
tissues belong to the foundations of regenerative medicine. However, 
the available sources of pluripotent cells until recently, were either 
unsuitable for this use (like ECCs) or faced ethical and other practical 
problems like immunorejection (like ESCs). The recent derivation of 
iPS cells is still facing problems like the low yield of cells, the 
increased carcinogenic potential as well as problems arising from their 
derivation with use of virus vectors.  For these reasons isolation for 
the first time of pluripotent cells from an adult tissue like maGSCs, 
without any genetic selection or induction should be regarded as a 
revolution in this field.  
 
However, very little is known until now about the mechanisms that 
may control pluripotency in maGSCs. Only recently was possible to 
derive similar cells also from human adult testis (Conrad et al.2008). 
However, these cells differ in many aspects form human ESCs and 
mouse maGSCs, especially in that it was not able to produce a clonal 
cell line from them. Since this characteristic is common in all other 
pluripotent cell types, future attempts should focus on elucidation of 
the nature of these cells isolated from the human adult testis. 
 
This work revealed in maGSCs a miRNA profile almost identical to 
that of ESCs and thus it solidifies the relationship between maGSCs 
and other pluripotent stem cells (i.e., ESCs, F9 ECCs) in rodents.  
 
In addition, it implies that maGSCs possess some unique 
characteristics concerning the way expression levels of pluripotency 
related miRNAs respond to differentiation. These characteristics may 
be connected with the PGC like gene expression profile that these 
cells present during differentiation and their relative resistance to 
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induction to differentiation. It remains to be elucidated in future 
studies whether this applies also to the in vitro derivatives of PGCs, 
the EGCs.   
 
Finally, this work lays the foundations for future functional studies 
concerning the role of miRNAs of miR-290, miR-302 and oncomirs` 
families in mesoderm formation and germ cell differentiation. The 
questions that have arisen need to be addressed by studies involving 
overexpression and downregulation of these miRNAs in vitro, as well 
as in vivo. 
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5.   Summary  
 
 
Spermatogonial stem cells (SSCs) isolated from the adult mouse testis 
and cultured have been shown to respond to culture conditions and 
become pluripotent, so called multipotent adult germline stem cells 
(maGSCs). Recently a new group of non coding RNAs, called 
microRNAs (miRNAs), has been implicated to play a key role in 
regulation of embryonic development and pluripotency in mouse 
embryonic stem cells (ESCs).  The objective of the current study was 
to test similarities and differences  between maGSCs and ESCs with 
respect to miRNAs. Whole miRNA array expression profiling showed 
that despite slight differences in expression of some oncomirs, 
undifferentiated maGSCs and ESCs originating from 129/Sv mouse 
strain are equivalent cell types from the viewpoint of microRNAome. 
In contrast, undifferentiated maGSCs originating from the transgenic 
Stra8-EGFP-Rosa mouse are a distinct cell type regarding miRNAs. 
miRNAs belonging to the 290 and 302 clusters have been previously 
classified as ESC-specific. This study shows that these miRNAs 
generally characterize pluripotent cells. They are expressed not only in 
undifferentiated ESCs but also in undifferentiated maGSCs as well as 
in the F9 embryonic carcinoma cell (ECC) line. In addition, this study 
tested the time-dependent influence of different factors that promote 
loss of pluripotency on levels of these miRNAs in all three pluripotent 
cell types. Using standard methods to induce ESC differentiation, this 
study showed loss of stem cell markers and miR-290 family 
expression in ESCs. Likewise, maGSC cultures lost pluripotent 
marker expression and miR-290 family expression was strongly 
attenuated, albeit slower than in ESCs. In addition, ESC 
differentiation with gelatin led to a marked and early upregulation of 
the miR-302 family that was lost over time, while a slow and steady 
upregulation was  observed in maGSCs treated similarly. Differences 
in time and extent of differentiation observed between ESCs and 
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maGSCs correspond to similar differences in the expression profiles 
of both miRNA families, suggesting similar underlying mechanisms 
in maintenance of pluripotency between the two cell types. These 
results indicate that the 290-miRNA family is connected with Oct-4 
and maintenance of the pluripotent state. In contrast, members of the 
302-miRNA family are induced during first stages of in vitro 
differentiation in all cell types tested. Therefore, detection of miRNAs 
of miR-302 family in pluripotent cells could be attributed to the 
proportion of spontaneously differentiating cells in cultures of 
pluripotent cells.  Furthermore, differences in the miRNA levels 
observed between ESCs and maGSCs correlate with differences 
observed in expression of de novo DNA methyltransferases and global 
methylation state in these cells. All these results are consistent with 
ESC-like nature of maGSCs and their potential as an alternative 
source of pluripotent cells from non-embryonic tissues. At the same 
time, however, they imply that the mechanisms that control 
differentiation in pluripotent cells may differ in some aspects between 
ESCs and maGSCs, and miRNAs may be responsible for these 
differences. 
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6.  Appendices 
 
 
Appendix 1 
 
 
 
Figure 1. Overview of early stages of mouse embryonic development and 
differentiation potential of cells from the three germ layers. The point lines and 
the different colours separate embryonic from extra embryonic tissues. The 
arrows connect each developmental stage with the previous stage from which it 
originates. The legends on the right define the differentiation potential of the 
cells, while the colour boxes at the bottom present examples of tissues 
orginating from each of the three germ layers. 
___________________________________________________________________________ 
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Figure 2. Sources of different types of pluripotent cells. Each subfigure 
represent a different pluripotent cell type in vitro with its respective origin cell 
population in vivo.  
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Figure 3. Transcription factors controlling pluripotency in mouse ESCs. The 
core of ESC transcriptional network consists of three transcription factors (Oct-
4, Nanog and Sox-2) that interact with each other and control expression of 
hundreds of genes. Arrows depict a positive effect through transcriptional 
activation. Blind arrows depict a negative effect through transcriptional 
inhibition. Circles include known target genes for each transcriptional factor. 
Overlapping regions show genes regulated in common from these factors either 
synergistically or independently (modified by Pan and Thomson 2007 and 
Rodda et al. 2005).  
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Appendix 2 
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Figure 1.  Example of PAGE electrophoresis of the PCR amplicons for 
members of miR-290 family in ESC R1 cells. These cells were further used as 
positive controls for construction of standard curves in qPCR. Similar were the 
results for miR-302a, b and d. 
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Figure 2.  Example of sequence  analysis of the cloned PCR amplicons for 
members of miR-290 and 302 family. In the figure the sequence for miR-
291_3p amplicon is presented. The presented alignment below the sequence is 
the result of comparison of the amplicon sequence with all mature miRNA 
sequences in Sanger miRNA database. Amplicon sequence marked in red 
corresponds to the mature miR-291_3p sequence in Sanger database, confirming 
the specificity of the PCR product. Sequence analysis confirmed the specificity 
of PCR products of all other miRNAs tested except miR-302c, as well as of 
Vimentin, Nestin, Brachyury, Hnf-4, Nkx-2.5, Oct-4, Dnmt3a, Dnmt3b and 
Sdha. 
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Figure 3.  Specificity and reliability of qPCR results was tested with the 
respective dissociation curves. The existence of only one peak in all runs 
confirmed the specificity of the PCR results. In this example dissociation curve 
of the PCR for miR-292_3p in ESC R1 cells is presented. Similar curves were 
obtained for all other miRNA and mRNA genes tested except miR-302c were 
the analysis showed multiple peaks.  
 
 
 
 
Appendices                                                                                                         123  
       
___________________________________________________________________________ 
 
Figure 4.  Example of test of RNA integrity (with the respective RIN values) for 
RNA used in miRNA array experiments. Acceptable are RIN values at least 
above 7. All samples tested in this study fulfilled this requirement (ESRI=ESC 
R1, ESSTR8=ESC STRA8, SSCSTR8=maGSC STRA8, SSC129SV=maGSC 
129SV). 
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Appendix 3 
 
A. Expression profiles of members of the miRNA 290 family in ESCs and maGSCs (Results, 
Section 3.4.3.). In this figure the different conditions are superimposed to facilitate 
comparison. 
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B. Expression profiles of members of the miRNA 302 family in ESCs and maGSCs (Results, 
Section 3.4.4.). In this figure the different conditions are superimposed to facilitate 
comparison. The upper part depicts results in ESCs, the lower part in maGSCs. Because of the 
strong upregulation of miRNA levels under Gel condition as compared to other culture 
conditions the results are given separately (left column).  
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Appendix 4 
 
A. Expression profiles of members of the miRNA 290 family in ESCs and maGSCs from 
mouse strain 129/Sv (ESC R1 and maGSC 129SV) under different culture conditions after 5 
,10 and 21 days (Subfigures a, b and c respectively)  in culture. a, b, c and d depicted in each 
subfigure above the different conditions indicate statistical significance for the following pair 
comparisons, a: comparison of each differentiation condition with untreated cells, b: 
comparison between FL+LIF+RA and GEL, c: comparison between FL+LIF+RA and 
GEL+RA, d: comparison between GEL and GEL+RA. Combination of two or three letters 
indicates statistical significance for more than one comparisons. For example, a b d above 
GEL condition refers to comparison of this condition with all other conditions. The letters 
apply to all miRNAs of each condition with the exception of these miRNAs with an # above 
them, which indicates no statistical significance for the corresponding miRNA and the 
corresponding comparison. For example #a above miRNA-290 in one condition means no 
statistical significance for miR-290 in this condition compared with untreated cells. The line 
that cuts the diagram in two parts, separates ESCs (left) from maGSCs (right). All levels were 
normalised to endogenous control (RNU6B) and calibrated to the value of untreated ESC R1 
(FL+LIF) at day 5 (subfigure a). 
 
 
B. Expression profiles of members of the miRNA 302 family in ESCs and maGSCs from 
mouse strain 129/Sv (ESC R1 and maGSC 129SV) under different culture conditions after 5, 
10 and 21 days in culture (Subfigures a, b and c respectively). The line that cuts the diagram 
in two parts, separates ESCs (left) from maGSCs (right). All levels were normalised to 
endogenous control (RNU6B) and calibrated to the value of untreated ESC R1 (FL+LIF) at 
day 5 (Fig.a). For symbols indicating statistical significance, see Figure A. Additionally, 
asterisk  above miR-302a in subfigure b indicates statistical significance only for this miRNA 
for the comparison of the respective condition with untreated cells. 
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Appendix 5 
 
Expression profiles of differentiation markers (Vimentin, Nestin, Hnf-4 and Nkx-2.5) in ESCs 
and maGSCs from mouse strain 129/Sv (ESC R1 and maGSC 129SV) under different culture 
conditions after 5 ,10 and 21 days in culture (vertical lines separate differentiation conditions 
of the same day from those of other days). Asterisks indicate statistical significance for the 
comparison with untreated cells. All levels were normalised to endogenous control (Sdha) and 
calibrated to the value of untreated ESC R1 (ESC R1 FL+LIF at day 5). (a) Expression profile 
in differentiating ESC R1 cells. (b) Expression profile in differentiating maGSC 129SV cells. 
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Appendix 6 
 
Detailed array results from experiments A and B. The tables depict statistical significant 
differentially expressed miRNAs for each of the comparisons mentioned in the text (Results, 
Section 3.8.). Values in the second column demonstrate fold change 2X, where X is the 
number in red or green. Each comparison has the format ‘cell line A-cell line B’. Red means 
that B>A, green that B>A. Padj =the adjusted P value. Expr = Experiment. 
 
ESC Stra8-maGSC Stra8 Expr A 
 
Gene Name
ESC Stra8-
maGSC Stra8 
ExprA 
Padj 
miRPlus_17952 -6.0 0.00479 
mmu-miR-762 -5.7 0.00404 
miRPlus_21472 -5.0 0.00304 
mmu-miR-712* -4.9 0.0015 
hsa-miR-193a-5p -4.7 0.00159 
hsa-miR-663 -4.6 0.00404 
hsa-miR-30b* -4.6 0.0022 
mmu-miR-720 -4.5 0.0078 
hsa-miR-623 -4.5 0.00658 
hsa-miR-492 -4.4 0.00488 
hsa-miR-671-5p -4.4 0.00396 
miRPlus_17890 -4.4 0.0015 
hsa-miR-498 -4.3 0.0013 
mmu-miR-711 -4.3 0.00159 
hsa-miR-371-5p -4.2 0.0015 
miRPlus_27561 -4.2 0.00788 
hsa-miR-602 -4.1 0.00304 
miRPlus_28431 -4.0 0.00612 
miRPlus_27560 -3.9 0.0013 
mmu-miR-689 -3.7 0.00188 
rno-miR-542-5p -3.5 0.00396 
hsa-miR-557 -3.2 0.00854 
miRPlus_17921 -3.0 0.0166 
hsa-miR-518c* -2.9 0.0015 
miRPlus_28575 -2.8 0.00902 
hsa-miR-638 -2.7 0.0207 
mmu-miR-184 -2.6 0.0035 
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hsa-miR-503 -2.5 0.00733 
mmu-miR-301a -2.4 0.0133 
mmu-miR-21 -2.4 0.00614 
miRPlus_27564 -2.3 0.00316 
mmu-miR-494 -2.2 0.00159 
hsa-miR-302c* -2.2 0.0295 
rno-miR-376b-3p 2.0 0.00658 
 
 
 
maGSC Stra8-maGSC129SV ExprA 
 
Gene Name
maGSC Stra8-
maGSC129SV 
ExprA 
Padj 
mmu-miR-335-
5p -4.2 0.0334 
mmu-miR-124 -3.9 0.00833 
mmu-miR-182 -3.8 0.00628 
mmu-miR-96 -3.7 0.0072 
mmu-miR-183 -2.6 0.00896 
hsa_SNORD13 -2.5 0.00546 
mmu-miR-292-
3p -2.5 0.00546 
mmu-miR-295 -2.3 0.00809 
mmu-miR-22 -2.2 0.0229 
mmu-miR-294 -2.0 0.0167 
mmu-miR-711 2.1 0.00905 
mmu-miR-494 2.1 0.00406 
rno-miR-142-
5p 2.1 0.0285 
mmu-miR-142-
5p 2.1 0.0273 
miRPlus_17921 2.5 0.031 
mmu-miR-720 2.5 0.0399 
hsa-miR-638 2.5 0.0285 
mmu-miR-706 2.6 0.00905 
rno-miR-542-
5p 2.6 0.00908 
miRPlus_28431 2.9 0.0165 
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miRPlus_17890 3.1 0.00384 
hsa-miR-602 3.2 0.00809 
hsa-miR-302d 3.2 0.0214 
miRPlus_27561 3.3 0.0186 
miRPlus_17952 3.3 0.0229 
hsa-miR-671-
5p 3.4 0.00905 
hsa-miR-30b* 3.4 0.00679 
mmu-miR-689 3.5 0.00406 
miRPlus_27560 3.6 0.00185 
hsa-miR-492 3.7 0.00905 
hsa-miR-623 3.7 0.0135 
hsa-miR-557 3.8 0.00855 
hsa-miR-663 3.9 0.00855 
hsa-miR-193a-
5p 4.1 0.00406 
miRPlus_21472 4.2 0.0072 
mmu-miR-142-
3p 4.3 0.0167 
hsa-miR-498 4.4 0.00185 
hsa-miR-371-
5p 4.4 0.00384 
mmu-miR-762 4.6 0.00859 
 
 
maGSC129SV-ESC_RI Expr A 
 
Gene Name maGSC129SV-ESC_RI Expr A Padj 
mmu-miR-20a -3.2 0.00482 
mmu-miR-17 -3.2 0.00482 
hsa-miR-106a -2.9 0.00482 
mmu-miR-19b -2.8 0.00482 
mmu-miR-20b -2.6 0.0163 
mmu-miR-467b -2.6 0.00482 
mmu-miR-
467a*/467d* -2.4 0.00531 
mmu-miR-106a -2.1 0.00783 
mmu-miR-805 -2.0 0.00936 
mmu-miR-22 2.5 0.0216 
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mmu-miR-689 2.6 0.00783 
hsa_SNORD13 2.8 0.00482 
 
 
 
 
 
 
ESC_RI-maGSC129 ExprB 
 
Gene Name ESC_RI-maGSC129 ExprB Padj 
miRPlus_1789
9 -2.2 0.0767 
mmu-miR-20b 3.5 0.0767 
rno-miR-290 4.8 0.0767 
mmu-miR-19b 5.4 0.0767 
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Multipotent adult germline stem cells and embryonic
stem cells have similar microRNA profiles
Athanasios Zovoilis1,5, Jessica Nolte1, Nadja Drusenheimer1, Ulrich Zechner2, Hiroki Hada1,
Kaomei Guan3, Gerd Hasenfuss3, Karim Nayernia4 and Wolfgang Engel1
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Spermatogonial stem cells (SSCs) isolated from the adult mouse testis and cultured have been shown to respond to culture con-
ditions and become pluripotent, so called multipotent adult germline stem cells (maGSCs). microRNAs (miRNAs) belonging to the
290 and 302 miRNA clusters have been previously classified as embryonic stem cell (ESC) specific. Here, we show that these
miRNAs generally characterize pluripotent cells. They are expressed not only in ESCs but also in maGSCs as well as in the F9
embryonic carcinoma cell (ECC) line. In addition, we tested the time-dependent influence of different factors that promote loss
of pluripotency on levels of these miRNAs in all three pluripotent cell types. Despite the differences regarding time and extent
of differentiation observed between ESCs and maGSCs, expression profiles of both miRNA families showed similarities
between these two cell types, suggesting similar underlying mechanisms in maintenance of pluripotency and differentiation.
Our results indicate that the 290-miRNA family is connected with Oct-4 and maintenance of the pluripotent state. In contrast,
members of the 302-miRNA family are induced during first stages of in vitro differentiation in all cell types tested. Therefore,
detection of miRNAs of miR-302 family in pluripotent cells can be attributed to the proportion of spontaneously differentiating
cells in cultures of pluripotent cells. These results are consistent with ESC-like nature of maGSCs and their potential as an alterna-
tive source of pluripotent cells from non-embryonic tissues.
Keywords: multipotent adult germline stem cells; embryonic stem cells; microRNAs; Oct4; pluripotency markers
Introduction
Embryonic stem cells (ESCs) are known to be pluripotent cells having
the capacity to self-renew as well as the ability to generate all types
of differentiated cells. However, ESCs face immune reaction after
transplantation and there are ethical issues regarding the usage of
embryos. Several studies have revealed that the germline lineage
retains the potential to generate pluripotent cells. In 2004, ESC-like
cells were found in germ stem cell cultures established from neonatal
mouse testis, designated as multipotent germline stem cells (Kanatsu-
Shinohara et al., 2004). In 2006, we have isolated and cultured for
the first time spermatogonial stem cells (SSCs) from the adult
mouse testis which respond to culture conditions and acquire ESC
properties (Guan et al., 2006). We proved that the pluripotency and
plasticity of these cells, which were named multipotent adult germline
stem cells (maGSCs), were similar to ESCs. They are able to spon-
taneously differentiate into derivatives of the three embryonic germ
layers in vitro, to generate teratomas in immunodeficient mice and
to contribute to the development of various organs when injected
into an early blastocyst. Isolation of these cells is not restricted to
the transgenic Stra8-EGFP/ROSA26 mouse. We have successfully
obtained ESC-like cell lines derived from testes of three different
strains of mice (FVB, C57BL/6 and 129/Sv) by morphological criteria
only. Our results were confirmed by other groups (Seandel et al., 2007;
Izadyar et al., 2008). Interestingly, another group showed recently
that SSCs are not pluripotent but that a single SSC can dedifferentiate
from a highly lineage-specified state to a pluripotent state (Kanatsu-
Shinohara et al., 2008). Since pluripotent cells have not been reported
for human testes until now, the mouse is a necessary model system for
the study of these cells.
In this study, we were interested to substantiate the ESC-like nature
of maGSCs with respect to microRNA (miRNA) expression. miRNAs
represent a recently identified class of cellular RNAs that regulate
protein expression at the translational level. The mature miRNAs
are 17–24 bp single-stranded RNA molecules which are expressed
in eucaryotic cells and affect the translation or stability of target
mRNAs (Bartel, 2004; Bartel and Chen, 2004). Each miRNA seems
to be able to regulate multiple genes. It was shown recently that
the expression of certain genes is more dependent on the level of
regulatory miRNAs than on the level of mRNAs that encode the
proteins (Johnson et al., 2005).
Recently, a set of miRNAs was described to be ESC-specific in
mouse, with their expression being repressed during ESC differen-
tiation and undetectable in adult mouse organs. This set of miRNAs
consists of miR-290, miR-291a-3p, miR-292-3p, miR-293, miR-294
and miR-295 (miR-290 family), and miR-302a, miR-302b,
miR-302c and miR-302d (miR-302 family). In a previous work,
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miRNAs of the miR-290 family were repressed in embryoid bodies
(EBs) prepared by culturing ESC for 14 days in either the presence
or absence of retinoic acid (RA), and it was suggested that their
expression is specific for pluripotent ES cells and is either silenced
or down-regulated upon differentiation (Houbaviy et al., 2003,
2005). Another group confirmed the expression of these miRNAs as
well as of those of miR-302 family only in mESCs and mEBs, and
not in somatic tissues. In addition, they reported a negative correlation
in EBs between miRNAs of miR-302 family and differentiation time
(Strauss et al., 2006; Chen et al., 2007). These miRNAs are expressed
in clusters (members of each miR-family are transcribed as parts of the
same pri-miRNA) and they have close homologues in human ESCs
with the same expression profile during differentiation (Suh et al.,
2004). However, their role in pluripotency is still not well defined.
In this study, we show that these miRNAs generally characterize
pluripotent cells, since maGSCs share with ESCs the unique chara-
cteristic of expressing these miRNAs. Furthermore, we show that
members of miR-302 family are induced during first stages of
in vitro differentiation.
Materials and Methods
Culture of mouse maGSC and ESC lines
The culture of maGSC lines from mouse lines 129/Sv (maGSC 129SV),
C57BL/6 (maGSC C57BL), FVB (maGSC FVB) and from the transgenic
line Stra8-EGFP/ROSA26 (maGSC Stra8) was described previously (Guan
et al., 2006). The ESC R1 line was derived from the 129/Sv mouse line
(Wurst and Joyner, 1993). The ESC line ESC Stra8 was generated from the
transgenic Stra8-EGFP/ROSA26 mouse as described previously (Cheng
et al., 2004). To maintain maGSCs and ESCs in an undifferentiated state, the
cells were cultured under standard ESC culture conditions: DMEM (PAN,
Aidenbach, Germany) supplemented with 20% fetal calf serum (PAN),
2 mM L-glutamine (Pan), 50 mM b-mercaptoethanol (Gibco/Invitrogen,
Eggenstein, Germany), 1 non-essential amino acids (Gibco/Invitrogen),
sodium pyruvate (Gibco/Invitrogen), penicillin/streptomycin (PAN). maGSCs
and ESCs were cultured on a feeder layer of mitomycin C-inactivated mouse
embryonic fibroblasts (MEFs) in the presence of 1000 U/ml recombinant
mouse leukaemia inhibitory factor (LIF) (Chemicon, Temecula, USA). For
the differentiation studies, the following culture conditions were used: (A)
ESC medium with fibroblasts (FL) and LIF (FLþLIF); (B) ESC medium
with FL, LIF and RA (1026 M) (Sigma-Aldrich, Steinheim, Germany) (FLþ
LIFþRA); (C) cells were cultured in 0.1% gelatine-coated culture flasks
with ESC medium, without LIF (Gel); (D) cells cultured in 0.1% gelatine-
coated culture flasks with ESC medium, without LIF but with RA
(GelþRA). In order to eliminate the impact of FL on the accuracy of the
results from cells cultured under conditions A and B, cells were cultured for
5 days (two passages) on 0.1% gelatine instead of FL prior to miRNA and
protein extraction. F9 cells were obtained from ATCC (Manassas, USA) and
cultured as described previously (Nayernia et al., 2004).
miRNA and mRNA analysis
Total RNA including miRNAs was isolated from cultured cells and from testes
of wild-type 129/Sv mouse using the miRNeasy mini Kit (Qiagen, Hilden,
Germany). Conversion of miRNA and mRNA into cDNA and real-time PCR
detection of miRNAs was carried out according to the manufacturer’s protocols
using the miScript Reverse Transcription Kit and miScript SYBR Green PCR
Kit (Qiagen) on an ABI Prism 7900HT Sequence Detection System. Optimized
miRNA-specific primers for each miRNA as well as for the endogenous control
RNU6B are also commercially available (miScript Primer Assays, Qiagen). All
experiments were performed in duplicate and PCR specificity was checked by
melting curves, gel electrophoresis and sequencing of the PCR products after
gel extraction and cloning into a pGEM-T Easy vector (Promega, Madison,
USA). On the basis of preliminary results, we decided not to include
miR-302c in our study, since the high amount of unspecific products observed
for this miRNA could not guarantee reliability of the results. The ESC R1 line
was used to prepare the standard curve for both the target miRNA and RNU6B,
to which all quantities were further normalized, and as calibrator. The ESC R1
(Fig. 1b) was of a higher passage number of the ESC R1 used in all other
experiments. Moreover, RNA from MEFs was used to exclude the possibility
of contamination due to FL. For real-time quantitative RT–PCR of Nestin,
Vimentin, Hnf4, Nkx2.5 and Sdha, to which all quantities were further
normalized, the QuantiTect SYBR-Green PCR MasterMix (Qiagen) was
used with gene-specific primers provided in Supplementary Table S1.
Protein isolation, western blotting and immunofluorescence
For isolation of proteins from cultured cells, cell pellets were resuspended in
lysis buffer (10 mM Tris/HCl, pH 8, 1 mM EDTA, 2.5% SDS) containing
1 mM phenylmethanesulphonylfluoride and proteinase inhibitors and were
sonificated. For protein isolation from mouse testis, 30 mg of tissue was
homogenized in the lysis buffer. Protein extracts (20 mg) were denaturated at
708C in NuPage SDS sample buffer (Invitrogen, Karlsruhe, Germany)
Figure 1: Expression levels of ESC-specific miRNAs detected by real-time PCR.
(a) miRNA expression in different maGSC lines, F9 cells, MEFs, NIH/3T3 cells and testis. ESC R1 (of a different passage number of that used in all other exper-
iments) was used as calibrator (cal). (b) miRNA expression levels in ESC R1 and maGSC 129SV of passages 15 and 25. (c) miRNA expression levels in untreated
ESC R1 and maGSC 129SV cells compared with the respective cells cultured for 35 days in gelatine-coated flasks without LIF but with RA (GelþRA). Asterisks
indicate statistical significance.
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containing 0.1 mM dithiothreitol (DTT), separated on NuPage 10% Bis-Tris
Gel (Invitrogen) and transferred on a Hybond-C extra membrane (GE Health-
care Europe, Freiburg, Germany). Blots were blocked for unspecific binding
and were incubated overnight at 48C with primary and for 1 h at 48C with
secondary HRP-conjugated antibody. Protein bands were visualized using
enhanced chemiluminescence as described by the manufacturer (Santa Cruz
Biotechnology, USA). When the expected band size allowed it, membranes
were reused for one more time and were incubated with another primary anti-
body after blocking. The following antibodies were used: a-Tubulin dilution
1:5000 (Sigma-Aldrich, T5168), anti-rabbit and anti-mouse IgG-peroxidase
antibodies (Sigma-Aldrich), Oct-4 dil 1:500 (Abcam, Cambridge, UK,
ab19857), Sox-2 dil 1:1000 (Abcam, ab15830), Zfp-206 (gift from Dr
L. Stanton, Singapore) and Sall-4 dil 1:500 (Abcam, ab29112). For immuno-
fluorescence staining of SSEA-1, the ES Cell Characterization Kit (Chemicon)
was used as described by the manufacturer. An anti-rabbit IgG Cy3-conjugated
antibody (Sigma-Aldrich) was used as secondary antibody and slides were
stained with DAPI (Vectashield, Vector Laboratories, Burlingame, USA).
Slides were viewed in a BX60 fluorescence microscope (Olympus, Hamburg,
Germany). Levels of Oct-4 and Sox-2 from western blots of two independent
experiments were quantified densitometrically with QuantityOne software
(Bio-Rad, Muenchen, Germany) and normalized to a-Tubulin.
Statistical analysis
Data are expressed as the mean+SD. A one-way analysis of variance
(ANOVA) followed by Fisher LSD’s multiple comparison tests was used for
statistical analysis with P , 0.05 considered statistically significant.
Results
maGSCs express standard pluripotency markers
as well as Sall-4 and Zfp-206
In order to evaluate the pluripotency of the cells used in the
experiments, the expression of pluripotency markers Oct-4, Sox-2,
Zfp-206 and Sall-4 was determined at the protein level (Scho¨ler
et al., 1989; Rodda et al., 2005; Buitrago and Roop, 2007; Masui
et al., 2007; Pan and Thomson, 2007). Zfp-206 and Sall-4 have
been shown recently to be expressed in ESCs and become down-
regulated during ESC differentiation (Zhang et al., 2006; Wang
et al., 2007). As it can be seen in Supplementary Fig. S1a, b and
S2a, the pluripotency markers are highly expressed in all maGSC
lines derived from different mouse strains (maGSC 129SV, maGSC
Stra8, maGSC FVB and maGSC C57BL). The expression of Oct-4,
Sox-2 in ESC R1 and ESC Stra8 and of Sall-4 and Zfp-206 in ESC
R1 was used as control. The pluripotency marker proteins could not
be detected by western analysis in testis nor in inactivated MEFs.
As can be seen in Supplementary Fig. S2a, the expression of Oct-4
and Sox-2 in ESC and maGSC lines remains unchanged during
passages 15–25. When cultured under differentiation conditions for
35 days (cells in 0.1% gelatine-coated flasks with 1026 M RA),
Oct-4, Sox-2 and SSEA-1 are down-regulated in ESC lines as well
as in maGSC lines (Supplementary Fig. S2a and b).
ESC-specific miRNAs are expressed in maGSCs
A specific set of miRNAs is known to be present in pluripotent ESCs.
These miRNAs can be demonstrated in ESC and maGSC lines of
different mouse strains, whereas no expression was detected in
MEFs, NIH 3T3 cells and testis (Fig. 1a). Interestingly, miRNA
expression pattern of maGSC Stra8 differed from maGSCs derived
from other mouse strains by demonstrating lower and higher levels
of miR-290 and miR-302 family, respectively. In addition, differences
were observed between maGSC 129SV and ESCs from the same
mouse strain (ESC R1). We examined whether ESC and maGSC
lines retain the expression of the specific miRNAs after culture for
many passages. Cells of passage 15 from the mouse strain 129/Sv
were cultivated for 35 days (10 passages; P25) under standard ESC
culture conditions. miRNA expression levels were found to remain
relatively stable despite slight differences between both cell types
(Fig. 1b). Under differentiation conditions for 35 days (cells on
0.1% gelatine in the presence of 1026 M RA), however, ESCs as
well as maGSCs lost their specific miRNA signature (Fig. 1c).
Members of miR-290 family are connected with maintenance
of pluripotency
We examined the effects of different factors that are commonly used
for in vitro differentiation of pluripotent cells on the expression of
members of ESC-specific miRNA families 290 and 302 in maGSCs
in comparison with ESCs. Figure 2a summarizes the strategy we
followed. ESCs and maGSCs of passage P16 from the mouse strain
129/Sv (ESC R1 and maGSC 129SV, respectively) were cultivated
for 5, 10 and 21 days under different culture conditions: feeder layer
(FL), LIF and RA (FLþLIFþRA); 0.1% gelatine-coated flasks
(Gel); 0.1% gelatine-coated flasks and RA (GelþRA). We also
studied cells that were cultivated for 5 days in 0.1% gelatine-coated
flasks and then induced by RA for 5 days (GelþRA from Day 5).
Cells were collected at Day 5, 10 and 21 and expression of miRNAs
was determined.
To assess the degree of differentiation, we determined the levels of
Oct-4 and Sox-2 proteins by western analysis, and the expression of
differentiation markers like Nestin, Vimentin, Hnf4 and Nkx2.5 was
analysed by qRT–PCR. Figure 2b shows that, after 5 days under FLþ
LIFþRA condition, the expression of Oct-4 and Sox-2 is strongly
down-regulated in ESCs and maGSCs. After culture of the cells for
5 days under GelþRA condition, Oct-4 expression is hardly detect-
able in maGSCs and absent in ESCs. Furthermore, no Sox-2
expression is detected. However, culture under Gel condition for 5
days was found to result in down-regulation of both pluripotency
marker proteins only in ESCs, but not in maGSCs. In maGSCs,
Oct-4 protein levels are similar to those of untreated cells. Only
after cultivation of maGSCs under Gel condition for a longer period
(21 days), Oct-4 expression is down-regulated (Fig. 2c).
Expression pattern of the differentiation markers tested differed
between ESCs and maGSCs. In ESCs (Fig. 3a), Vimentin and
Nestin are significantly increased under GelþRA condition at Day 5
(Vimentin also under FLþLIFþRA condition), and in all three differ-
entiation conditions at Day 10. At Day 21, they are down-regulated
under all conditions, and only Nkx2.5 is increased under Gel and
GelþRA conditions at that day. Expression of Hnf4 is significantly
up-regulated only at Day 5 under GelþRA condition. In contrast in
maGSCs (Fig. 3b), no significant change in the expression of these
markers takes place at Day 5 and 10, with the exceptions of Nestin,
Vimentin and Hnf4 under FLþLIFþRA condition at Day 10 and a
slight increase of Nkx2.5 under Gel condition at Day 10. Only at
Day 21, an increase of Vimentin and Nestin expression under
GelþRA condition and of Nestin under Gel condition is observed.
At Day 21, expression of Nkx2.5 and Hnf4 were restricted to under
Gel and GelþRA conditions, respectively.
ESCs and maGSCs differed also concerning expression levels
between GelþRA and GelþRA from Day 5 condition. Compared
with GelþRA condition, levels of Nestin and Vimentin in ESCs
were lower when RA was added from Day 5, whereas in maGSCs
Nestin, Vimentin and Nkx2.5 were increased under this condition
and only Hnf4 levels were lower (Supplementary Fig. S3c).
We then studied the effects of the different culture conditions on the
expression of members of miRNA families 290 and 302 in ESCs and
maGSCs. Figure 4 shows the expression profile of miRNAs of the
290-family in ESCs and maGSCs during culture (5–21 days) under
microRNA signature in maGSCs
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all differentiation conditions used as well as in untreated cells. In both
ESCs and maGSCs, all members of the 290-family are constantly
expressed or even increased in untreated cells, although in the case
of maGSCs at lower levels (50% of ESC expression in some cases)
comparing with ESCs. In ESCs, these miRNAs are down-regulated
at Day 5 of culture under all differentiation conditions with the stron-
gest effect observed in GelþRA condition (Fig. 4a). At Day 10 and 21,
miRNA levels can hardly be detected under all differentiation con-
ditions (Fig. 4b and c). In maGSCs at Day 5, levels of miRNAs do
not decrease in Gel and GelþRA conditions (with the exception of
miR-290 in GelþRA). Their expression is the same or even higher
than in untreated cells (Fig. 4a). At Day 10, miRNA levels have
further increased in Gel condition (Fig. 4b). In GelþRA condition
at Day 10, miRNA levels do not increase further but they are still
high, whereas a strong down-regulation at Day 10 is observed only
under FLþLIFþRA condition (Fig. 4b). At Day 21, miRNA levels
of cells in Gel condition are lower than those of untreated cells
(with the exception of miR-290), but remain still high in comparison
with the other two conditions (GelþRA and FLþLIFþRA), where
miRNAs are hardly detectable (Fig. 4c).
Finally, in maGSCs if RA is added from Day 5 onwards (GelþRA
from Day 5), miRNA levels at Day 10 are lower compared with
GelþRA condition, where RA was added from the beginning, con-
trasting with ESC R1 (Supplementary Fig. S3a).
Members of miR-302 family are induced during first stages
of in vitro differentiation
The expression profiles of members of the 302-family were found to
differ significantly from those of miR-290 family members (Fig. 5).
In ESCs, the Gel condition has an extreme effect on the expression
of miRNAs 302 at Day 5 (Fig. 5a). They become strongly up-regulated
Figure 2: Cell culture strategy and determination of Oct-4 and Sox-2 protein expression during differentiation of ESCs and maGSCs from 129/Sv mouse strain
(ESC R1 and maGSC 129SV).
(a) Cells were cultured for 5, 10 and 21 days under different culture conditions. FLþLIF: on feeder layer with LiF (untreated cells); FLþLIFþRA: on feeder layer
with LiF and RA; Gel: in gelatine-coated flasks alone; GelþRA from Day 5: on gelatine for 5 days followed by addition of RA to the culture medium for another 5
days; GelþRA: on 0.1% gelatine in the presence of RA. (b) Expression of Oct-4 and Sox-2 in ESCs and maGSCs cultured for 5 days under the above-mentioned
conditions. Quantification of Oct-4 and Sox-2 was done by densitometry. Expression levels were compared between untreated and differentiating cells, asterisks
indicate statistical significance. a-Tubulin served as loading control. (c) Expression of Oct-4 in untreated maGSCs (FLþLIF) and in maGSCs under Gel condition
over time (5, 10 and 21 days). Quantification of western blotting results was done by densitometer and normalized to the levels of a-Tubulin. Single asterisk indicates
statistical significance between Day 5 and Day 10, double asterisks between Day 10 and Day 21.
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(20–100-fold increase). Their levels decrease rapidly after Day 5, but
even at Day 10 and 21 of culture, the miRNA expression is still higher
than that in untreated cells (Fig. 5b and c). In GelþRA, miRNA levels
increase temporally to levels higher than that in untreated cells around
Day 10 (Fig. 5b). Then they decrease leading to expression levels
lower than that in untreated cells at Day 21. In contrast, when RA is
added from Day 5 onwards, such an increase at Day 10 does not
occur (Supplementary Fig. S3b). miRNAs 302 also become
up-regulated in maGSCs under Gel condition. During the culture
period of 21 days, expression levels increase 10–30-fold (Fig. 5c).
However, in the case of maGSCs, levels increase gradually at least
until Day 21, and not only at Day 5 like in ESCs. In the other two
conditions (GelþRA and FLþLIFþRA), miRNA levels at Day 5
are higher than those in untreated cells (Fig. 5a) and become similar
to them thereafter (Fig. 5b and c). The increase from Day 5 to Day
10 observed in Gel is weaker (especially for mir-302b and d) when
RA is added from Day 5 onwards (GelþRA from Day 5), but
miRNA levels in this condition are still higher compared with
GelþRA at the same day (Supplementary Fig. S3b).
ESC-specific miRNAs are expressed in teratocarcinoma
cell line F9
In addition, we studied the expression of ESC-specific miRNAs in the
teratocarcinoma cell line F9 [embryonic carcinoma cell (ECCs)] that
was found to share many similarities with pluripotent cells
(Andrews, 2002). As can be seen from Supplementary Fig. S1a and
Fig. 1a, ECCs express the pluripotency markers Oct-4 and Sox-2 as
well as the ESC-specific set of miRNA families 290 and 302. In the
past, RA has been used to induce differentiation of these cells
(Alonso et al., 1991). When ECCs are treated with 1026 M RA for
25 days, miR-290 and miR-291 levels decrease slightly, miR-292,
miR-293 and miR-294 levels remain relatively stable and only
miR-295 increases. In contrast, the levels of all miR-302 family
members increase significantly (3–5-fold increase) (Fig. 6a). Both
treated and untreated cells express the pluripotency markers Oct-4
and Sox-2 (Fig. 6b), but in treated cells an increase in the levels of
differentiation markers Nestin and Hnf4 is observed (Fig. 6c).
Discussion
Previously, several authors have described a unique miRNA
expression signature in mouse ESCs. Members of 290 and 302
miRNA families were previously classified as ESC-specific, since
they are expressed only in undifferentiated ESCs. Expression of
these miRNAs in ESC EBs is strongly down-regulated when ESCs
are induced to differentiate and undetectable in adult organs (this,
however, does not apply to miR-302 family during early in vitro
differentiation as we show in the present study). Our results show
that maGSCs share this unique miRNA expression signature with
ESC lines. These miRNAs are also constantly expressed in maGSCs
and down-regulated after long exposure to differentiation conditions.
However, expression levels differed between maGSCs from different
mouse strains, as well as between ESCs and maGSCs from the same
mouse strain. A possible explanation for this, apart from the different
genetic background, could be the different passage number of the cell
lines tested. As shown in Figs 1b, 4 and 5, even under standard ESC
culture conditions miRNA expression levels vary between different
passage numbers (which, for example, in the case of miR-293 demon-
strates an increase in expression levels of more than 50% in untreated
ESCs at Day 21, Fig. 4c, compared with untreated ESCs at Day 5,
Fig. 4a). maGSCs Stra8 was the maGSC line of the highest passage
number used in this study, which could explain the different
miRNA expression pattern compared with the other maGSC lines
that are of lower passage number. For this reason in all other exper-
iments, cell lines of the same passage number and the same mouse
strain (129/Sv) were used to eliminate this effect. In this case, when
cell lines of the same passage number are used, maGSCs 129SV
seem to express these miRNAs in lower levels than ESCs from the
Figure 3: Expression profiles of differentiation markers (Vimentin, Nestin, Hnf4 and Nkx2.5) in ESCs and maGSCs from mouse strain 129/Sv (ESC R1 and
maGSC 129SV) under different culture conditions after 5, 10 and 21 days in culture (vertical lines separate differentiation conditions of the same day from
those of other days).
Asterisks indicate statistical significance for the comparison with untreated cells. All levels were normalized to endogenous control (Sdha) and calibrated to the value
of untreated ESC R1 (ESC R1 FLþLIF at Day 5). (a) Expression profile in differentiating ESC R1 cells. (b) Expression profile in differentiating maGSC 129SV
cells.
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same background (ESC R1). We also detected these miRNAs in high
levels in F9 teratocarcinoma cells, which have also been shown to be
pluripotent (Andrews, 2002). Thus, it is shown that these miRNAs
generally characterize pluripotent cells. However, in contrast to F9
cells, proliferation and expression of these markers in maGSCs are
restricted to standard ESC culture conditions. This is an important
similarity between ESCs and maGSCs that distinguishes them
from ECCs.
Several authors have studied expression profiles of members of
miRNA families 290 and 302 during ESC differentiation. They
found a negative correlation between their expression levels and
differentiation over time (Houbaviy et al., 2003; Strauss et al.,
2006; Chen et al., 2007). Because ESCs and maGSCs share great
similarities in pluripotency (Kanatsu-Shinohara et al., 2004, 2008;
Guan et al., 2006; Seandel et al., 2007) (Supplementary Figs S1 and
S2), we decided to study the profiles of both miRNA families
during differentiation of both cell types. Owing to the high number
of differentiation strategies so far described, we concentrated on the
most important factors that prevent or induce differentiation in ESC
culture, namely LIF and RA, respectively (Rohwedel et al., 1999;
Rao, 2004; Kurosawa, 2007; Tighe and Gudas, 2004; Liu et al.,
2007). Loss of pluripotent state of the cells tested was evaluated by
determining expression levels of well-known pluripotency markers
as well as differentiation markers like Nestin (neural stem cell
marker) (Lin et al., 1995; Lendahl, 1997; Wiese et al., 2004),
Vimentin (early neuro-ectoderm formation and cells of mesodermal
origin) (Franke et al., 1982; Boisseau and Simonneau, 1989; Colucci-
Guyon et al., 1999), Hnf4 (endoderm) (Taraviras et al., 1994; Duncan
et al., 1997) and Nkx2.5 (early embryo heart formation) (Liberatore
et al., 2002).
The observation of other authors that the members of miRNA
family 290 are down-regulated in ESCs during differentiation is sup-
ported by our results and a down-regulation was found to be realized
during maGSCs differentiation. However, in maGSCs under Gel and
Figure 4: Expression profiles of members of the miRNA 290 family in ESCs and maGSCs from mouse strain 129/Sv (ESC R1 and maGSC 129SV) under different
culture conditions after 5, 10 and 21 days (Fig. 4a, b and c, respectively) in culture.
a, b, c and d depicted in each subfigure above the different conditions indicate statistical significance for the following pair comparisons, a: comparison of each
differentiation condition with untreated cells, b: comparison between FLþLIFþRA and GEL, c: comparison between FLþLIFþRA and GELþRA, d: comparison
between GEL and GELþRA. Combination of two or three letters indicates statistical significance for more than one comparison. For example, a b d above GEL
condition refers to comparison of this condition with all other conditions. The letters apply to all miRNAs of each condition with the exception of these miRNAs with
a # above them, which indicates no statistical significance for the corresponding miRNA and the corresponding comparison. For example #a above miRNA-290 in
one condition means no statistical significance for miR-290 in this condition compared with untreated cells. The line that cuts the diagram into two parts separates
ESCs (left) from maGSCs (right). All levels were normalized to endogenous control (RNU6B) and calibrated to the value of untreated ESC R1 (FLþLIF) at Day 5
(Fig. 4a).
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GelþRA condition, miRNA levels remain high for a longer period
than in ESCs or even increase transiently (Gel condition). These
differences seem to correlate with the differences in the differentiation
status of these cells. Under Gel condition, Nestin and Vimentin are
up-regulated earlier in ESCs, whereas Oct-4 expression decreases
later in maGSCs. In addition, FLþLIFþRA, which is the only
condition in maGSCs at Day 10 with a significant increase in most
differentiation markers, is characterized by a strong down-regulation
of miRNA levels. Since the expression profile of Oct-4 corresponds
to that of members of miRNA family 290 in both ESCs and
maGSCs, our results indicate that expression of these miRNAs
is more connected with maintenance of pluripotency than with
differentiation.
Chen et al. have studied expression of members of the miRNA 302
family in ESCs at Days 3, 6 and 9 during EB formation in the absence
of LIF. They found that these miRNAs are negatively correlated to
differentiation time (Chen et al., 2007). This expression profile in
ESCs is different from that we obtained in our study, since during
the first 5 days of differentiation under Gel condition, all members
of miRNA family 302 are strongly up-regulated. Transient
up-regulation of these miRNAs in ESCs is also observed in the pre-
sence of RA, although not so strongly as in Gel condition. Expression
profiles of these miRNAs in maGSCs demonstrate similarities and
differences compared with ESCs. Under Gel condition, strong
up-regulation of miRNA levels is also observed, and addition of RA
was found to result also in an up-regulation of these miRNAs.
However, in maGSCs up-regulation under Gel condition takes place
slowly. At Day 21, miRNA levels in maGSCs depict 10–30-fold
increase, whereas in ESCs 20–100-fold increase is reached already
at Day 5. This gradual increase in maGSCs correlates to the differ-
ences in differentiation status between ESCs and maGSCs mentioned
above. In addition, the increase under GelþRA condition in maGSCs
occurs at Day 5 and not at Day 10 as in ESCs.
Since the expression profile of Oct-4 does not correspond to that of
302 miR-family members, our results suggest that these miRNAs are
more connected with response of pluripotent cells to differentiation
than with the undifferentiated state itself. This is in contradiction to
the observation that, even in undifferentiated cells, miRNAs 302 are
present but can be explained by the observation that cultures of
pluripotent cells contain spontaneously differentiated cells (Houbaviy
et al., 2003).
The connection of members of miRNA family 290 with pluripo-
tency and that of members of miRNA family 302 with the process
of differentiation is further supported by our miRNA analysis in
ECCs and by comparing GelþRA condition with GelþRA from
Day 5 condition. In ECCs (Fig. 6), where addition of RA is followed
by an increase in Nestin and Hnf4 expression, miR-302 family is
up-regulated. At the same time, treated cells retain expression of
miR-290 family as they do for Oct-4. When GelþRA and GelþRA
from Day 5 conditions are compared, high levels of miR-290 family
are connected with low levels of miR-302 family and most of
differentiation markers (with the exception of Hnf4) and vice versa.
This connection is also supported by the findings of Tang et al.
They have shown that the miRNA 290 family belongs to the most
significant miRNAs strongly up-regulated in early mouse embryogen-
esis from 2-cell stage onwards (Tang et al., 2007). This is exactly the
stage when Oct-4 expression increases (Scho¨ler et al., 1989). In con-
trast, miRNA family 302 does not show significant expression
changes. However, the exact correlation of miR-302 expression with
a specific lineage commitment requires differentiation strategies that
are beyond the scope of this study and the simple differentiation
model used here. In addition, it was recently shown that miRNAs
of the miR-290 family control de novo DNA methylation through
regulation of transcriptional repressors in mouse ESCs (Sinkkonen
et al., 2008) which implies that differences observed during differen-
tiation between ESCs and maGSCs may be connected with the
differences observed in the miRNA level.
miRNAs are believed to play a crucial role in development by reg-
ulating expression of hundreds of genes simultaneously. Members of
miRNA families 290 and 302, which were previously classified as
ESC specific, are candidates for such a role in pluripotent stem cells
and not only in mouse, since they have close homologues in human
ESCs with similar expression profile during differentiation. Our
results support further the connection of miR-290 family with main-
tenance of pluripotency and provide indirect evidence for a possible
role of members of miR-302 family during first stages of in vitro
Figure 5: Expression profiles of members of the miRNA 302 family in ESCs
and maGSCs from mouse strain 129/Sv (ESC R1 and maGSC 129SV) under
different culture conditions after 5, 10 and 21 days in culture (Fig. 5a, b and
c, respectively).
The line that cuts the diagram into two parts separates ESCs (left) from
maGSCs (right). All levels were normalized to endogenous control (RNU6B)
and calibrated to the value of untreated ESC R1 (FLþLIF) at Day 5
(Fig. 5a). For symbols indicating statistical significance, see Fig. 4. Addition-
ally, asterisk above miR-302a in Fig. 5b indicates statistical significance only
for this miRNA for the comparison of the respective condition with untreated
cells.
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differentiation of pluripotent cells. Moreover, detection of these
miRNAs in maGSCs is consistent with the ESC-like nature of
maGSCs and their potential as an alternative source of pluripotent
cells.
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 LEGENDS TO FIGURES IN SUPPLEMENTARY DATA 
Figure S1. Expression of pluripotency markers in different ESC lines, maGSC lines, F9 
cells, mouse testis and MEFs. (a) Oct-4 and Sox-2; the same membrane 
was used for both antibodies. The reason why no Oct-4 was detected in the 
testis sample although previous reports demonstrate Oct-4 immunoreactivity 
by histochemical methods from embryonic through adult testes could be 
attributed to the fact that spermatogonial stem cells constitute only 0.03% of 
all germ cells making it difficult  to detect by Western analyis.  (b) Zfp-206 
and Sall-4. a-Tubulin served as loading control. Cal = calibrator 
Figure S2. Expression of pluripotency markers in ESCs and maGSCs from 129/Sv 
background (ESC R1 and maGSC 129SV) and  after culture. Cells were 
cultured  for 35 days under standard ESC culture conditions (from passage 
15 to passage 25) and in 0.1% gelatine coated flasks without LIF but with RA 
(Gel+RA). (a) Western Blotting for Oct-4 and Sox-2. Levels of Oct-4 and Sox-
2 were quantified densitometrically. Asterisks indicate statistical significance 
in comparison with untreated cells. (b) Immunostaining for SSEA-1.  The ES 
cell characterization kit (chemicon) was used to immunostain for SSEA-1 with 
Cy3-conjugated anti-rabbit 1gG secondary antibody. 
Figure S3. Comparison of expression levels of members of miRNAs and differentiation 
markers at day 10 in ESCs and maGSCs from mouse strain 129/Sv (ESC R1 
and maGSC 129SV) between Gel+RA (cells cultured in Gel coated flasks 
with addition of RA from the beginning) and Gel+RA from day 5 (cells 
cultured in Gel coated flasks with addition of RA from day 5) conditions. The 
 line that cuts the diagram in two parts, separates ESCs (left) from maGSCs 
(right). All miRNA and mRNA levels were normalised to endogenous control 
(RNU6B and Sdha respectively) and calibrated to the value of untreated ESC 
R1 (FL+LIF) at day 5. Asterisk indicates statistical significance comparing 
with Gel  +RA from day 0 condition. # indicates no statistical significance (a) 
Expression levels of miR-290 family. (b) Expression levels of miR-302 family 
. (c) Expression levels of Vimentin,Nestin, Hnf4 and Nkx2.5 



Supplementary Table 1:
Primers used in qRT-PCR of Vimentin, Hnf4, Nestin, Nkx2.5 and Sdha
5-CATCTCCAGTTGTCCTCTTCCA-3mSdha-R
5-GCTTGCGAGCTGCATTTGG-3mSdha-F
5-GTCCAGCTCCACTGCCTTCTG-3mNkx2.5-R
5-CCCAAGTGCTCTCCTGCTTTCC-3mNkx2.5-F
5-ATTAGGCAAGGGGGAAGAGA-3mNestin-R
5-CTGCAGGCCACTGAAAAGTT-3mNestin-F
5-CGCTCATTTTGGACAGCTTC-3mHNF4-R
5-CCACATGTACTCCTGCAGGTTTAG-3mHNF4-F
5-ATCTCTTCATCGTGCAGTTTCTTC-3mVimentin-R
5-TGCAGTCATTCAGACAGGATGT-3mVimentin-F
SequencePrimer name
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